<SUBMISSION>
<ACCESSION-NUMBER>0000936392-08-000514
<TYPE>424B2
<PUBLIC-DOCUMENT-COUNT>3
<FILING-DATE>20080808
<DATE-OF-FILING-DATE-CHANGE>20080807
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>ILLUMINA INC
<CIK>0001110803
<ASSIGNED-SIC>3826
<IRS-NUMBER>330804655
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>0101
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>424B2
<ACT>33
<FILE-NUMBER>333-134012
<FILM-NUMBER>08999981
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>9885 TOWNE CENTRE DRIVE
<CITY>SAN DIEGO
<STATE>CA
<ZIP>92121
<PHONE>8582024500
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>9885 TOWNE CENTRE DRIVE
<CITY>SAN DIEGO
<STATE>CA
<ZIP>92121
</MAIL-ADDRESS>
</FILER>
<DOCUMENT>
<TYPE>424B2
<SEQUENCE>1
<FILENAME>a42519fe424b2.htm
<DESCRIPTION>FORM 424(B)(2)
<TEXT>
<HTML>
<HEAD>
<TITLE>e424b2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Filed pursuant to Rule 424(b)(2)
</DIV>

<DIV align="right" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    File No. 333-134012
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Calculation of
    Registration Fee</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="29%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutterright -->
    <TD width="20%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutterright -->
    <TD width="17%">&nbsp;</TD>	<!-- colindex=03 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutterright -->
    <TD width="16%">&nbsp;</TD>	<!-- colindex=04 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterleft -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutterright -->
    <TD width="10%">&nbsp;</TD>	<!-- colindex=05 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
    <B>Proposed<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Proposed maximum<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>maximum<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Amount of<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>Title of each class of securities to be<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>offering price per<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>aggregate offering<BR>
    </B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>registration<BR>
    </B>
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
    <B>registered</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>Amount to be registered</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>unit</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>price</B>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom">
    <B>fee</B>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="top" style="border-top: 1px solid #000000">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Common stock, par value $0.01 per share, including related
    rights to purchase Series&#160;A Junior Participating Preferred
    Stock<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    4,025,000&#160;shares<SUP style="font-size: 85%; vertical-align: text-top">(2)</SUP>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    $87.50<SUP style="font-size: 85%; vertical-align: text-top">(3)</SUP>
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    $352,187,500
</TD>
<TD style="border-right: 1px solid #000000; padding-right: 2pt; border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD nowrap align="center" valign="bottom" style="border-top: 1px solid #000000">
    $13,841<SUP style="font-size: 85%; vertical-align: text-top">(4)</SUP>
</TD>
</TR>
<TR style="font-size: 1pt">
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom" style="border-top: 3px double #000000">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>    (1)&#160;
</TD>
    <TD align="left">    Each share of the registrant&#146;s common stock being
    registered hereunder, if issued before the termination of the
    registrant&#146;s preferred share rights agreement, includes
    Series&#160;A Junior Participating Preferred Stock purchase
    rights. Before the occurrence of certain events, the
    Series&#160;A Junior Participating Preferred Stock purchase
    rights will not be exercisable or evidenced separately from the
    registrant&#146;s common stock and have no value except as
    reflected in the market price of the shares to which they are
    attached.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>




<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>    (2)&#160;
</TD>
    <TD align="left">    Includes shares that the underwriter may purchase pursuant to
    its option, described in this prospectus supplement, to purchase
    additional shares.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>




<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>    (3)&#160;
</TD>
    <TD align="left">    Represents the initial public offering price per share.
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>




<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>    (4)&#160;
</TD>
    <TD align="left">    A filing fee of $13,841 has been transmitted to the SEC in
    connection with the securities offered pursuant to this
    prospectus supplement.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Prospectus Supplement to Prospectus dated May&#160;11, 2006.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 14pt">3,500,000&#160;Shares
    </FONT>
</DIV>

<DIV style="margin-top: 4pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <IMG src="a42519fa4251900.gif" alt="(ILLUMINA LOGO)"><FONT style="font-size: 14pt">
    </FONT>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 16pt">Illumina, Inc.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 14pt">Common Stock
    </FONT>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 29%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=132 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Illumina, Inc. is offering 3,500,000&#160;shares to be sold in
    the offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The common stock is listed on The NASDAQ Global Select Market
    under the symbol &#147;ILMN.&#148; The last reported sale price
    of the common stock on August&#160;6, 2008 was $89.25 per share.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <I>See &#147;Risk Factors&#148; beginning on
    <FONT style="white-space: nowrap">page&#160;S-7</FONT>
    of this prospectus supplement to read about factors you should
    consider before buying shares of the common stock.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 29%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=132 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <B>Neither the Securities and Exchange Commission nor any other
    regulatory body has approved or disapproved of these securities
    or passed upon the adequacy or accuracy of this prospectus
    supplement or the accompanying prospectus. Any representation to
    the contrary is a criminal offense.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 29%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=132 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="69%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="14%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <FONT style="font-size: 10pt">Per Share
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <FONT style="font-size: 10pt">Total
    </FONT>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Initial price to public
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;87.50
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;306,250,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Underwriting discount
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,050,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Proceeds, before expenses, to Illumina, Inc.&#160;
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    85.20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    298,200,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    To the extent that the underwriter sells more than
    3,500,000&#160;shares of common stock, the underwriter has the
    option to purchase up to an additional 525,000&#160;shares from
    Illumina, Inc. at the initial price to public less the
    underwriting discount.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 29%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=132 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The underwriter expects to deliver the shares against payment in
    New York, New York on August&#160;12, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt">Goldman, Sachs&#160;&#038;
    Co.</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 29%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=132 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Prospectus Supplement dated August&#160;6, 2008.
</DIV>

<P align="left" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="94%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<!-- Table Width Row END -->
<TR valign="bottom">
<TD colspan="3" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Prospectus Supplement
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Page
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    About this Prospectus Supplement
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-2
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Prospectus Supplement Summary
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-3
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk Factors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-7
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Special Note Regarding Forward-Looking Statements
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-16
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Use of Proceeds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-17
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Price Range of Our Common Stock
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-18
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Dividend Policy
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-18
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Capitalization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-19
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Underwriting
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-20
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Where You Can Find More Information
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-23
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Incorporation of Certain Documents by Reference
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-23
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Legal Matters
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-24
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Experts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    S-24
</TD>
</TR>
<TR valign="bottom" style="line-height: 12pt">
<TD colspan="3">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" align="center" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD colspan="3" align="center" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Prospectus
</DIV>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    Page
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    About this Prospectus
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    1
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Risk Factors
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    2
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Use of Proceeds
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    9
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Where You Can Find More Information
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    9
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Incorporation of Certain Document by Reference
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    9
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Legal Matters
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    10
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Experts
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="center" valign="top">
    10
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 18%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    No dealer, salesperson or other person is authorized to give any
    information or to represent anything not contained in this
    prospectus supplement and the accompanying prospectus. You must
    not rely on any unauthorized information or representations.
    This propsectus supplement and the accompanying prospectus are
    an offer to sell only the shares offered hereby, but only under
    circumstances and in jurisdictions where it is lawful to do so.
    The information contained in this prospectus supplement and the
    accompanying prospectus is current only as of their respective
    dates.
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 18%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=84 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-1
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='101'>
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">ABOUT THIS
    PROSPECTUS SUPPLEMENT</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    This document is in two parts. The first part is this prospectus
    supplement, which describes the specific terms of this offering
    of our common stock. The second part, the accompanying
    prospectus dated May&#160;11, 2006, gives more general
    information about us and our common stock. You should read this
    prospectus supplement and the accompanying prospectus, including
    the information incorporated by reference and any free writing
    prospectuses we have authorized for use in connection with this
    offering, in their entirety before making an investment decision.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    You should rely only on the information contained or
    incorporated by reference in this prospectus supplement and the
    accompanying prospectus, along with the information contained in
    any free writing prospectuses we have authorized for use in
    connection with this offering. We have not, and the underwriter
    has not, authorized anyone to give you different or additional
    information. You should not assume that the information included
    or incorporated by reference in this prospectus supplement and
    accompanying prospectus is accurate as of any date after the
    respective dates of the documents containing the information.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Unless the context requires otherwise, the words
    &#147;Illumina,&#148; &#147;we,&#148; &#147;company,&#148;
    &#147;us&#148; and &#147;our&#148; refer to Illumina, Inc. and
    its subsidiaries, and the term &#147;you&#148; refers to a
    prospective investor.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    This prospectus supplement, the accompanying prospectus and the
    documents incorporated by reference include trademarks, service
    marks and trade names owned by us or others. All trademarks,
    service marks and trade names included or incorporated by
    reference in this prospectus supplement or the accompanying
    prospectus are the property of their respective owners.
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    S-2
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->
<A name='102'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">PROSPECTUS
    SUPPLEMENT SUMMARY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <I>This summary highlights selected information appearing
    elsewhere or incorporated by reference in this prospectus
    supplement and the accompanying prospectus and may not contain
    all of the information that is important to you. This prospectus
    supplement and the accompanying prospectus include information
    about the shares we are offering as well as information
    regarding our business and detailed financial data. You should
    read this prospectus supplement, the accompanying prospectus and
    any free writing prospectuses we have authorized for use in
    connection with this offering in their entirety, including the
    information incorporated by reference.</I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Business
    Overview</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We are a leading developer, manufacturer and marketer of
    next-generation life sciences tools and integrated systems for
    the large-scale analysis of genetic variation and biological
    function. Using our proprietary technologies, we provide a
    comprehensive line of products and services that currently serve
    the sequencing, genotyping and gene expression markets. In the
    future, we expect to enter the market for molecular diagnostics.
    Our customers include leading genomic research centers,
    pharmaceutical companies, academic institutions, clinical
    research organizations and biotechnology companies. Our tools
    provide researchers around the world with the performance,
    throughput, cost effectiveness and flexibility necessary to
    perform the billions of genetic tests needed to extract valuable
    medical information from advances in genomics and proteomics. We
    believe this information will enable researchers to correlate
    genetic variation and biological function, which will enhance
    drug discovery and clinical research, allow diseases to be
    detected earlier and permit better choices of drugs for
    individual patients.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Recent
    Developments</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    On August&#160;1, 2008, we closed our acquisition of Avantome
    Inc., a development-stage company. The primary purpose of the
    acquisition was to obtain Avantome&#146;s low-cost, long-read
    sequencing technology. As consideration for the acquisition, we
    paid $25.0&#160;million in cash up front and may pay up to an
    additional $35.0&#160;million in contingent cash consideration
    based on the achievement of certain milestones.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    On July&#160;22, 2008, we announced that our board of directors
    approved a
    <FONT style="white-space: nowrap">two-for-one</FONT>
    stock split to be effected in the form of a stock dividend. The
    stock split is subject to stockholder approval of a proposed
    amendment to our certificate of incorporation to increase the
    number of authorized shares of our common stock from
    120&#160;million to 500&#160;million. We intend to seek approval
    of this amendment to our certificate of incorporation at a
    special meeting of our stockholders, which we expect to hold on
    September&#160;9, 2008. If the amendment is approved, we
    anticipate that the record date for the stock split will be
    September&#160;10, 2008 and that the payment date for the stock
    split will be September&#160;22, 2008. Our board of directors
    retains the right to change the amount of the stock dividend or
    not to effect the dividend at all.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Our Corporate
    Information</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We were incorporated in California in April 1998 and
    reincorporated in Delaware in July 2000. Our principal executive
    offices are located at 9885 Towne Centre Drive, San&#160;Diego,
    California 92121, and our telephone number is
    <FONT style="white-space: nowrap">(858)&#160;202-4500.</FONT>
    We maintain an Internet website at
    <FONT style="white-space: nowrap">http://www.illumina.com.</FONT>
    We have not incorporated by reference into this prospectus
    supplement or the accompanying prospectus the information in, or
    that can be accessed through, our website, and you should not
    consider it to be a part of this prospectus supplement or the
    accompanying prospectus.
</DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-3
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">The
    Offering</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="44%"></TD>
    <TD width="1%"></TD>
    <TD width="55%"></TD>
</TR>

<TR>
    <TD valign="top">
    <B>Common stock we are offering</B></TD>
    <TD></TD>
    <TD valign="bottom">
    3,500,000&#160;shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -4%; margin-left: 4%">
    <B>Common stock to be outstanding as<BR>
    of June&#160;29, 2008, as adjusted for<BR>
    this offering</B></DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    68,053,019&#160;shares</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -4%; margin-left: 4%">
    <B>Risk factors</B></DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    See &#147;Risk Factors&#148; beginning on
    <FONT style="white-space: nowrap">page&#160;S-7</FONT>
    and the other information included or incorporated by reference
    in this prospectus supplement and the accompanying prospectus
    for a discussion of the factors you should consider before you
    make an investment decision.</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -4%; margin-left: 4%">
    <B>The NASDAQ Global Select Market symbol</B></DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    ILMN</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR>
    <TD valign="top">
<DIV style="text-indent: -4%; margin-left: 4%">
    <B>Use of proceeds</B></DIV>
</TD>
    <TD></TD>
    <TD valign="bottom">
    See &#147;Use of Proceeds&#148; on
    <FONT style="white-space: nowrap">page&#160;S-17</FONT>
    for information on how we expect to use the net proceeds from
    this offering.</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The number of shares of our common stock outstanding as of
    June&#160;29, 2008, as adjusted for this offering, is based on
    64,553,019&#160;shares outstanding as of June&#160;29, 2008,
    including 7,409,545&#160;shares held in treasury, and excludes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="3%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    9,662,777&#160;shares of our common stock issuable upon exercise
    of options outstanding as of June&#160;29, 2008, at a weighted
    average exercise price of $30.45 per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    10,748,961&#160;shares of our common stock issuable upon
    exercise of warrants outstanding as of June&#160;29, 2008, at a
    weighted average exercise price of $56.54 per share;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    3,730,108&#160;shares of our common stock available for future
    grant under our equity incentive plans as of June&#160;29,
    2008;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    up to 9,161,160&#160;shares of our common stock, subject to
    adjustment, issuable upon conversion of our outstanding
    convertible notes.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Unless we specifically state otherwise, the information in this
    prospectus supplement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="3%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    does not give effect to our proposed
    <FONT style="white-space: nowrap">two-for-one</FONT>
    stock split;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    assumes that the underwriter does not exercise its option to
    purchase up to 525,000&#160;additional shares of our common
    stock.
</TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-4
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">SUMMARY
    CONSOLIDATED FINANCIAL DATA</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The following summary consolidated financial data for the years
    ended December&#160;30, 2007, December&#160;31, 2006 and
    January&#160;1, 2006 are derived from our audited consolidated
    financial statements that are incorporated by reference into
    this prospectus supplement. The following summary consolidated
    financial data for the six months ended June&#160;29, 2008 and
    July&#160;1, 2007, and as of June 29, 2008, are derived from our
    unaudited interim condensed consolidated financial statements
    that are incorporated by reference into this prospectus
    supplement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    This information is only a summary and should be read together
    with the consolidated financial statements, the related notes
    and the other financial information incorporated by reference
    into this prospectus supplement and on file with the SEC. For
    more details on how you can obtain our SEC reports incorporated
    by reference into this prospectus supplement, see &#147;Where
    You Can Find More Information.&#148;
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 8pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="44%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=04 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=04 type=lead -->
    <TD width="7%" align="right">&nbsp;</TD>	<!-- colindex=04 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=04 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=05 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=05 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=05 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=05 type=hang1 -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=06 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=06 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=06 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=06 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="10" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Year Ended</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>Six Months Ended</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>December&#160;30,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>December&#160;31,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>January&#160;1,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>June&#160;29,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>July&#160;1,<BR>
    </B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B>Statement of Operations Data</B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>2006</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>2008</B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B>2007</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="20" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    (in thousands, except per share data)
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="line-height: 9pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Revenue:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Product revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;326,699
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;155,811
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;57,752
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;239,235
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;135,562
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Service and other revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,100
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,775
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,749
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    22,803
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21,123
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    Total revenue
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    366,799
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    184,586
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    262,038
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    156,685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Costs and expenses:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Cost of product revenue (including non-cash stock compensation
    expense of $4,045, $1,289, $0, $2,642 and $1,839, respectively,
    excluding impairment of manufacturing equipment and amortization
    of intangible assets)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    119,991
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    51,271
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    19,920
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    89,673
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,850
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Cost of service and other revenue (including non-cash stock
    compensation expense of $279, $235, $0, $179 and $140,
    respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,445
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    8,073
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    3,261
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,867
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    6,412
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Research and development (including non-cash stock compensation
    expense of $10,016, $3,891, $84, $6,754 and $4,428, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    73,943
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    33,373
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27,809
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    34,140
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Selling, general and administrative (including non-cash stock
    compensation expense of $19,406, $8,889, $186, $13,556 and
    $9,056, respectively)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    101,256
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,057
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28,158
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69,443
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    46,930
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 24pt">
    Impairment of manufacturing equipment
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,069
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Amortization of intangible assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,429
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,084
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,104
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Acquired in-process research and development
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    303,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    15,800
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    303,400
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 16pt">
    Litigation settlements (judgment), net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,536
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 32pt">
    Total costs and expenses
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    668,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    146,774
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    94,948
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    219,193
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    440,836
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income (loss) from operations
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (301,201)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    37,812
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (21,447)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,845
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (284,151)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Interest and other income, net
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    12,416
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,808
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    736
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    4,410
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    5,066
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Income (loss) before income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (288,785)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42,620
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (20,711)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    47,255
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (279,085)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Provision (benefit) for income taxes
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (10,426)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    2,652
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    163
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    18,429
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    9,727
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net income (loss)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (278,359)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    39,968
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (20,874)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28,826
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (288,812)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net income (loss) per basic share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (5.14)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.90
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.52)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.51
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (5.39)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Net income (loss) per diluted share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (5.14)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.82
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (0.52)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    0.44
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    (5.39)
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Shares used in calculating basic net income (loss) per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,154
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    44,501
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    56,310
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,604
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -8pt; margin-left: 8pt">
    Shares used in calculating diluted net income (loss) per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    54,154
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    48,754
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40,147
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    65,231
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53,604
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-5
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<DIV style="width: 100%; height: 9in; border-top: 1px solid #000000; padding-top: 12pt; border-right: 1px solid #000000; padding-right: 12pt; border-bottom: 1px solid #000000; padding-bottom: 12pt; border-left: 1px solid #000000; padding-left: 12pt"><!-- Begin box 1 -->

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="71%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="11%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of June&#160;29, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    <B><FONT style="font-size: 9pt">Balance Sheet Data</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Actual</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">As
    Adjusted<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP></FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="8" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    (in thousands)
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash, cash equivalents and short-term investments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;303,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    601,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Working capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    20,608
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    318,458
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total assets
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    992,685
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,290,535
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Current portion of long-term debt
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    400,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term obligations, less current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    14,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Stockholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    491,752
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    789,602
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <I><FONT style="font-size: 8pt">(1) </FONT></I></TD>
    <TD></TD>
    <TD valign="bottom">
    <I><FONT style="font-size: 8pt">As adjusted to give effect to
    the sale of 3,500,000&#160;shares of common stock we are
    offering pursuant to this prospectus supplement at a public
    offering price of $87.50 per share, after deducting underwriting
    discounts and commissions and estimated offering expenses to be
    paid by us.</FONT></I></TD>
</TR>

</TABLE>
</DIV><!-- End box 1 -->

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    S-6
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='103'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">RISK
    FACTORS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <I>Investing in our common stock involves a high degree of risk.
    In addition to the other information included or incorporated by
    reference in this prospectus supplement or accompanying
    prospectus, or any free writing prospectus we have authorized in
    connection with this offering, you should carefully consider the
    risks described below before purchasing our common stock. If any
    of the following risks actually occurs, our business, results of
    operations and financial condition will likely suffer. As a
    result, the trading price of our common stock may decline, and
    you might lose part or all of your investment.</I>
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Risks Related to
    Our Business</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;We
    expect intense competition in our target markets, which could
    render our products obsolete, result in significant price
    reductions or substantially limit the volume of products that we
    sell. This would limit our ability to compete and maintain
    profitability. If we cannot continuously develop and
    commercialize new products, our revenue may not grow as
    intended.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We compete with life sciences companies that design, manufacture
    and market instruments for analysis of genetic variation and
    biological function and other applications using technologies
    such as two-dimensional electrophoresis, capillary
    electrophoresis, mass spectrometry, flow cytometry,
    microfluidics, nanotechnology, next-generation DNA sequencing
    and mechanically deposited, inkjet and photolithographic arrays.
    We anticipate that we will face increased competition in the
    future as existing companies develop new or improved products
    and as new companies enter the market with new technologies. The
    markets for our products are characterized by rapidly changing
    technology, evolving industry standards, changes in customer
    needs, emerging competition, new product introductions and
    strong price competition. For example, prices per data point for
    genotyping have fallen significantly over the last two years and
    we anticipate that prices will continue to fall. One or more of
    our competitors may render our technology obsolete or
    uneconomical. Some of our competitors have greater financial and
    personnel resources, broader product lines, a more established
    customer base and more experience in research and development
    than we do. Furthermore, life sciences and pharmaceutical
    companies, which are our potential customers and strategic
    partners, could develop competing products. For example, during
    the third quarter of fiscal 2007, Applied Biosystems, Inc.,
    launched the
    SOLiD<SUP style="font-size: 85%; vertical-align: text-top"><FONT style="font-variant: SMALL-CAPS">tm</FONT></SUP>
    System, its next generation sequencing technology. If we are
    unable to develop enhancements to our technology and rapidly
    deploy new product offerings, our business, financial condition
    and results of operations will suffer.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;We
    may encounter difficulties in managing our growth. These
    difficulties could impair our profitability.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We have experienced and expect to continue to experience rapid
    and substantial growth in order to achieve our operating plans,
    which will place a strain on our human and capital resources. If
    we are unable to manage this growth effectively, our
    profitability could suffer. Our ability to manage our operations
    and growth effectively requires us to continue to expend funds
    to enhance our operational, financial and management controls,
    reporting systems and procedures and to attract and retain
    sufficient numbers of talented employees. If we are unable to
    scale up and implement improvements to our manufacturing process
    and control systems in an efficient or timely manner, or if we
    encounter deficiencies in existing systems and controls, then we
    will not be able to make available the products required to
    successfully commercialize our technology. Failure to attract
    and retain sufficient numbers of talented employees will further
    strain our human resources and could impede our growth.
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-7
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;If
    we lose our key personnel or are unable to attract and retain
    additional personnel, we may be unable to achieve our
    goals.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We are highly dependent on our management and scientific
    personnel, including Jay Flatley, our president and chief
    executive officer. The loss of their services could adversely
    impact our ability to achieve our business objectives. We will
    need to hire additional qualified personnel with expertise in
    molecular biology, chemistry, biological information processing,
    sales, marketing and technical support. We compete for qualified
    management and scientific personnel with other life science
    companies, universities and research institutions, particularly
    those focusing on genomics. Competition for these individuals,
    particularly in the San&#160;Diego and San&#160;Francisco area,
    is intense, and the turnover rate can be high. Failure to
    attract and retain management and scientific personnel would
    prevent us from pursuing collaborations or developing our
    products or technologies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Our planned activities will require additional expertise in
    specific industries and areas applicable to the products
    developed through our technologies, including the life sciences
    and healthcare industries. Thus, we will need to add new
    personnel, including management, and develop the expertise of
    existing management. The failure to do so could impair the
    growth of our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;If
    we are unable to increase our manufacturing capacity and develop
    and maintain operation of our manufacturing capability, we may
    not be able to launch or support our products in a timely
    manner, or at all.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We continue to ramp up our capacity to meet the anticipated
    demand for our products. Although we have significantly
    increased our manufacturing capacity and we believe we have
    plans in place sufficient to ensure we have adequate capacity to
    meet our business plan for the remainder of 2008 and in 2009,
    there are uncertainties inherent in expanding our manufacturing
    capabilities and we may not be able to increase our capacity in
    a timely manner. For example, manufacturing and product quality
    issues may arise as we increase production rates at our
    manufacturing facilities and launch new products. As a result,
    we may experience difficulties in meeting customer, collaborator
    and internal demand, in which case we could lose customers or be
    required to delay new product introductions, and demand for our
    products could decline. Additionally, in the past, we have
    experienced variations in manufacturing conditions that have
    temporarily reduced production yields. Due to the intricate
    nature of manufacturing products that contain DNA, we may
    encounter similar or previously unknown manufacturing
    difficulties in the future that could significantly reduce
    production yields, impact our ability to launch or sell these
    products, or to produce them economically, prevent us from
    achieving expected performance levels or cause us to set prices
    that hinder wide adoption by customers.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Additionally, we currently manufacture in a limited number of
    locations. Our manufacturing facilities are located in
    San&#160;Diego and Hayward, California and Little Chesterford,
    United Kingdom. We are in the process of expanding our
    manufacturing operations into Singapore, a country in which we
    have no past manufacturing experience. These areas are subject
    to natural disasters such as earthquakes or floods. If a natural
    disaster were to significantly damage one of our facilities or
    if other events were to cause our operations to fail, these
    events could prevent us from manufacturing our products,
    providing our services and developing new products.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Also, many of our manufacturing processes are automated and are
    controlled by our custom-designed Laboratory Information
    Management System (LIMS). Additionally, as part of the decoding
    step in our array manufacturing process, we record several
    images of each array to identify what bead is in each location
    on the array and to validate each bead in the array. This
    requires significant network and storage infrastructure. If
    either our LIMS system or our networks or storage infrastructure
    were to fail for an extended period of time, it may adversely
    impact our ability to manufacture our products on a timely basis
    and would prevent us from achieving our expected shipments in
    any given period.
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-8
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;If
    we are unable to find third-party manufacturers to manufacture
    components of our products, we may not be able to launch or
    support our products in a timely manner, or at
    all.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The nature of our products requires customized components that
    currently are available from a limited number of sources. For
    example, we currently use multiple components in our products
    that are single-sourced. If we are unable to secure a sufficient
    supply of those or other product components, we will be unable
    to meet demand for our products. We may need to enter into
    contractual relationships with manufacturers for
    commercial-scale production of some of our products, or develop
    these capabilities internally, and we cannot assure you that we
    will be able to do this on a timely basis, for sufficient
    quantities or on commercially reasonable terms. Accordingly, we
    may not be able to establish or maintain reliable, high-volume
    manufacturing at commercially reasonable costs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;Our
    sales, marketing and technical support organization may limit
    our ability to sell our products.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We currently have fewer resources available for sales and
    marketing and technical support services compared to some of our
    primary competitors. In order to effectively commercialize our
    sequencing, genotyping and gene expression systems and other
    products to follow, we will need to expand our sales, marketing
    and technical support staff both domestically and
    internationally. We may not be successful in establishing or
    maintaining either a direct sales force or distribution
    arrangements to market our products and services. In addition,
    we compete primarily with much larger companies that have larger
    sales and distribution staffs and a significant installed base
    of products in place, and the efforts from a limited sales and
    marketing force may not be sufficient to build the market
    acceptance of our products required to support continued growth
    of our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;Any
    inability to protect effectively our proprietary technologies
    could harm our competitive position.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Our success will depend in part on our ability to obtain patents
    and maintain adequate protection of our intellectual property in
    the United States and other countries. If we do not protect our
    intellectual property adequately, competitors may be able to use
    our technologies and thereby erode our competitive advantage. In
    addition, the laws of some foreign countries do not protect
    proprietary rights to the same extent as the laws of the United
    States, and many companies have encountered significant
    challenges in protecting their proprietary rights abroad. These
    challenges can be caused by the absence of rules and methods for
    the establishment and enforcement of intellectual property
    rights abroad.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The patent positions of companies developing tools for the life
    sciences and pharmaceutical industries, including our patent
    position, generally are uncertain and involve complex legal and
    factual questions. We will be able to protect our proprietary
    rights from unauthorized use by third parties only to the extent
    that our proprietary technologies are covered by valid and
    enforceable patents or are effectively maintained as trade
    secrets. We intend to apply for patents covering our
    technologies and products as we deem appropriate. However, our
    patent applications may be challenged and may not result in
    issued patents or may be invalidated or narrowed in scope after
    they are issued. Questions as to inventorship may also arise.
    Any finding that our patents and applications are unenforceable
    could harm our ability to prevent others from practicing the
    related technology, and a finding that others have inventorship
    rights to our patents and applications could require us to
    obtain certain rights to practice related technologies, which
    may not be available on favorable terms, if at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    In addition, our existing patents and any future patents we
    obtain may not be sufficiently broad to prevent others from
    practicing our technologies or from developing competing
    products. There also is risk that others may independently
    develop similar or alternative technologies or design around our
    patented technologies. Accordingly, our patents may fail to
    provide us with any competitive advantage. We may also need to
    initiate lawsuits to protect or enforce our patents, or litigate
    against third party claims, which would be expensive and, if we
    lose, may cause us to lose some of our intellectual
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-9
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    property rights and reduce our ability to compete in the
    marketplace. These lawsuits may be costly and divert the
    attention of our management and technical personnel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We also rely upon trade secret protection for our confidential
    and proprietary information and have taken security measures to
    protect it. These measures, however, may not provide adequate
    protection for our trade secrets or other confidential
    information. Among other things, we seek to protect our trade
    secrets and confidential information by entering into
    confidentiality agreements with employees, collaborators and
    consultants. These employees, collaborators or consultants may
    nevertheless disclose our confidential information, and we may
    not otherwise be able to protect effectively our trade secrets.
    Accordingly, others may gain access to our confidential
    information, or may independently develop substantially
    equivalent information or techniques.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;Negative
    conditions in the global credit markets may impair the liquidity
    of a portion of our investment portfolio.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Our investment securities consist of marketable debt securities,
    including treasury bills and commercial paper with strong credit
    ratings, corporate bonds and short maturity mutual funds
    providing similar financial returns. Additionally, as of
    June&#160;29, 2008, we had $55.9&#160;million of auction rate
    securities issued primarily by municipalities and universities.
    These securities are debt instruments with a long-term maturity
    and with an interest rate that is reset in short intervals
    through auctions. The recent negative conditions in the global
    credit markets have prevented some investors from liquidating
    their holdings of auction rate securities because the amount of
    securities submitted for sale has exceeded the amount of
    purchase orders for such securities. If there is insufficient
    demand at the time of an auction for the securities we hold, the
    auction may not be completed and the interest rates may be reset
    to predetermined lower rates. When auctions for these securities
    fail, the investments may not be readily convertible to cash
    until a future auction of these investments is successful or
    they are redeemed or mature.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    All of our auction rate securities are currently rated AAA, the
    highest rating, by a rating agency. Although their credit
    ratings have not deteriorated, there has been insufficient
    demand at auction for all of our high-grade auction rate
    securities during the second quarter of 2008. As a result, these
    securities are currently not liquid. In the event we need to
    access the funds that are in an illiquid state, we will not be
    able to do so without a loss of principal, until a future
    auction on these investments is successful, the securities are
    redeemed by the issuer or they mature. As a result, we have
    recorded an unrealized loss of $3.1&#160;million for the six
    months ended June&#160;29, 2008, resulting in a reduction to the
    fair value of our auction rate securities to $52.8&#160;million
    as of June&#160;29, 2008. Due to the lack of actively traded
    market data, the value of these securities and resulting
    unrealized loss was determined using management&#146;s
    assumptions of pricing by market participants, including
    assumptions about risk, which requires the exercise of
    significant judgment. Although it could take until the final
    maturity of the underlying notes (ranging from 23&#160;years to
    39&#160;years) to realize the recorded value of these
    investments, we currently believe these securities are not
    permanently impaired, primarily due to the government guarantee
    of the underlying securities and our ability to hold these
    securities for the foreseeable future. Due to our intent to hold
    these securities until they recover in value, we have classified
    them as long-term investments on our balance sheet. Our cash and
    cash equivalents and short-term investments totaled
    $303.3&#160;million as of June&#160;29, 2008. Based on the
    liquidity of these funds and our projected cash flows from
    operations, we believe the illiquidity of these auction rate
    securities will not materially affect our ability to execute our
    current business plan.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;We
    may encounter difficulties in integrating acquisitions that
    could adversely affect our business, specifically the effective
    launch and customer acceptance of new technology
    platforms.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We acquired Solexa in January 2007, CyVera in April 2005, and
    Avantome in August 2008, and we may in the future acquire
    technology, products or businesses related to our current or
    future business. We have limited experience in acquisition
    activities and may have to devote substantial time and
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-10
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    resources in order to complete acquisitions. Further, these
    potential acquisitions entail risks, uncertainties and potential
    disruptions to our business. For example, we may not be able to
    successfully integrate a company&#146;s operations,
    technologies, products and services, information systems and
    personnel into our business. An acquisition may further strain
    our existing financial and managerial resources, and divert
    management&#146;s attention away from our other business
    concerns.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    In connection with these acquisitions, we assumed certain
    liabilities and hired certain employees, which is expected to
    continue to result in an increase in our research and
    development expenses and capital expenditures. There may also be
    unanticipated costs and liabilities associated with an
    acquisition that could adversely affect our operating results.
    To finance any acquisitions, we may choose to issue shares of
    our common stock as consideration, which could result in
    dilution to our stockholders. Additionally, an acquisition may
    have a substantial negative impact on near-term expected
    financial results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;Changes
    in our effective income tax rate could impact our
    profitability.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We are subject to income taxes in both the United States and
    numerous foreign jurisdictions. Significant judgments based on
    interpretations of existing tax laws or regulations are required
    in determining the provision for income taxes. Our effective
    income tax rate could be adversely affected by various factors
    including, but not limited to, changes in the mix of earnings in
    tax jurisdictions with different statutory tax rates, changes in
    the valuation of deferred tax assets and liabilities, changes in
    existing tax laws or tax rates, changes in the level of
    non-deductible expenses including share-based compensation,
    changes in our future levels of research and development
    spending, mergers and acquisitions, and the result of
    examinations by various tax authorities.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;Litigation
    or other proceedings or third party claims of intellectual
    property infringement could require us to spend significant time
    and money and could prevent us from selling our products or
    services or impact our stock price.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Our commercial success depends, in part, on our non-infringement
    of the patents or proprietary rights of third parties and on our
    ability to protect our own intellectual property. Third parties
    have asserted and may in the future assert that we are employing
    their proprietary technology without authorization. As we enter
    new markets, we expect that competitors will likely assert that
    our products infringe their intellectual property rights as part
    of a business strategy to impede our successful entry into those
    markets. In addition, third parties may have obtained and may in
    the future obtain patents allowing them to claim that the use of
    our technologies infringes these patents. We could incur
    substantial costs and divert the attention of our management and
    technical personnel in defending ourselves against any of these
    claims. Any adverse ruling or perception of an adverse ruling in
    defending ourselves against these claims could have a material
    adverse impact on our stock price, which may be disproportionate
    to the actual import of the ruling itself. Furthermore, parties
    making claims against us may be able to obtain injunctive or
    other relief, which effectively could block our ability to
    develop further, commercialize and sell products, and could
    result in the award of substantial damages against us. In the
    event of a successful claim of infringement against us, we may
    be required to pay damages and obtain one or more licenses from
    third parties, or be prohibited from selling certain products.
    In addition, we may be unable to obtain these licenses at a
    reasonable cost, if at all. We could therefore incur substantial
    costs related to royalty payments for licenses obtained from
    third parties, which could negatively affect our gross margins.
    In addition, we could encounter delays in product introductions
    while we attempt to develop alternative methods or products.
    Defense of any lawsuit or failure to obtain any of these
    licenses on favorable terms could prevent us from
    commercializing products, and the prohibition of sale of any of
    our products could materially affect our ability to grow and
    maintain profitability.
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-11
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;We
    have a significant amount of indebtedness. We may not be able to
    make payments on our indebtedness, and we may incur additional
    indebtedness in the future, which could adversely affect our
    operation and profitability.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    In February 2007, we issued $400.0&#160;million of
    0.625%&#160;convertible senior notes due February 2014. The
    notes bear interest semi-annually, mature on February&#160;15,
    2014 and obligate us to repurchase the notes at the option of
    the holders if a &#147;designated event&#148; (as defined in the
    indenture for the notes), such as certain merger transactions
    involving us, occurs. In addition, upon conversion of the notes,
    we must pay in cash the principal portion of the notes being
    converted. Our ability to make payments on the notes will depend
    on our future operating performance and our ability to generate
    cash and may also depend on our ability to obtain additional
    debt or equity financing. We may need to use our cash to pay
    principal and interest on our debt, which will reduce the funds
    available to fund our research and development programs,
    strategic initiatives and working capital requirements. Our
    ability to generate sufficient operating cash flow to service
    the notes and fund our operating requirements will depend on our
    continued ability to commercialize new products and expand our
    manufacturing capabilities. Our debt service obligations
    increase our vulnerabilities to competitive pressures, because
    our competitors may be less leveraged than we are. If we are
    unable to generate sufficient operating cash flow to service our
    indebtedness and fund our operating requirements, we may be
    forced to reduce our development programs or seek additional
    debt or equity financing, which may not be available to us on
    satisfactory terms, or at all, or may dilute the interests of
    our existing stockholders. Our level of indebtedness may make us
    more vulnerable to economic or industry downturns. If we incur
    new indebtedness, the risks relating to our business and our
    ability to service our indebtedness will intensify.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;We
    expect that our results of operations will fluctuate. This
    fluctuation could cause our stock price to
    decline.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Our revenue is subject to fluctuations due to the timing of
    sales of high-value products and services projects, the impact
    of seasonal spending patterns, the timing and size of research
    projects our customers perform, changes in overall spending
    levels in the life sciences industry, and other unpredictable
    factors that may affect customer ordering patterns. Given the
    difficulty in predicting the timing and magnitude of sales for
    our products and services, we may experience quarter-to-quarter
    fluctuations in revenue resulting in the potential for a
    sequential decline in quarterly revenue. A large portion of our
    expenses is relatively fixed, including expenses for facilities,
    equipment and personnel. In addition, we expect operating
    expenses to continue to increase significantly in absolute
    dollars. Accordingly, if revenue does not grow as anticipated,
    we may not be able to maintain annual profitability. Any
    significant delays in the commercial launch of our products,
    unfavorable sales trends in our existing product lines, or
    impacts from the other factors mentioned above, could adversely
    affect our future revenue growth or cause a sequential decline
    in quarterly revenue. Due to the possibility of fluctuations in
    our revenue and expenses, we believe that quarterly comparisons
    of our operating results are not a good indication of our future
    performance. If our operating results fluctuate or do not meet
    the expectations of stock market analysts and investors, our
    stock price could decline.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;We
    may not be able to sustain operating
    profitability.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Prior to 2006, we had incurred net losses each year since our
    inception, and in 2007 we reported a net loss of
    $278.4&#160;million, reflecting significant charges associated
    with our acquisition of Solexa in January 2007 and the
    settlement of our litigation with Affymetrix. As of
    June&#160;29, 2008, our accumulated deficit was
    $354.2&#160;million. Our ability to sustain profitability will
    depend, in part, on the rate of growth, if any, of our revenue
    and on the level of our expenses. Non-cash stock-based
    compensation expense and expenses related to our acquisition of
    Solexa are also likely to continue to adversely affect our
    future profitability. We expect to continue incurring
    significant expenses related to research and development, sales
    and marketing efforts to commercialize our products and the
    continued development of our manufacturing capabilities. In
    addition, we expect that our research and
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-12
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    development and selling and marketing expenses will increase at
    a higher rate in the future as a result of the development and
    launch of new products. Although we have regained profitability,
    we may not be able to sustain profitability on a quarterly basis.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;A
    significant portion of our sales is to international
    customers.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Approximately 48% and 31% of our revenue for the three months
    ended June&#160;29, 2008 and July&#160;1, 2007, respectively,
    was derived from shipments to customers outside the United
    States. Approximately 48% and 35% of our revenue for the six
    months ended June&#160;29, 2008 and July&#160;1, 2007,
    respectively, was derived from shipments to customers outside
    the United States. We intend to continue to expand our
    international presence by selling to customers located outside
    of the U.S.&#160;and we expect the total amount of
    <FONT style="white-space: nowrap">non-U.S.&#160;sales</FONT>
    to continue to grow. Export sales entail a variety of risks,
    including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="3%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    currency exchange fluctuations;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    unexpected changes in legislative or regulatory requirements of
    foreign countries into which we import our products;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    difficulties in obtaining export licenses or in overcoming other
    trade barriers and restrictions resulting in delivery delays;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    challenges in obtaining and enforcing patents abroad;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    significant taxes or other burdens of complying with a variety
    of foreign laws.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    In addition, sales to international customers typically result
    in longer payment cycles and greater difficulty in accounts
    receivable collection. We are also subject to general
    geopolitical risks, such as political, social and economic
    instability and changes in diplomatic and trade relations. One
    or more of these factors could have a material adverse effect on
    our business, financial condition and operating results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;Our
    success depends upon the continued emergence and growth of
    markets for analysis of genetic variation and biological
    function.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We design our products primarily for applications in the life
    sciences and pharmaceutical industries. The usefulness of our
    technology depends in part upon the availability of genetic data
    and its usefulness in identifying or treating disease. We are
    focusing on markets for analysis of genetic variation and
    biological function, namely sequencing, SNP genotyping and gene
    expression profiling. These markets are new and emerging, and
    they may not develop as quickly as we anticipate, or reach their
    full potential. Other methods of analysis of genetic variation
    and biological function may emerge and displace the methods we
    are developing. Also, researchers may not seek or be able to
    convert raw genetic data into medically valuable information
    through the analysis of genetic variation and biological
    function. In addition, factors affecting research and
    development spending generally, such as changes in the
    regulatory environment affecting life sciences and
    pharmaceutical companies, and changes in government programs
    that provide funding to companies and research institutions,
    could harm our business. If useful genetic data is not available
    or if our target markets do not develop in a timely manner,
    demand for our products may grow at a slower rate than we
    expect, and we may not be able to sustain profitability.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;We
    may not have the ability to pay the cash payments due upon
    conversion of our outstanding convertible notes.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    In February 2007, we issued $400.0&#160;million of 0.625%
    convertible senior notes due February 2014. The notes are
    convertible into cash and, if applicable, shares of our common
    stock only if specified conditions are satisfied. During the
    first quarter of 2008, we determined that one of these
    conditions was satisfied, and, accordingly, the notes were
    convertible from and including April&#160;1, 2008 through and
    including June&#160;30, 2008. The requirements of the same
    condition were again satisfied in the
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-13
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    second quarter of 2008, and, accordingly, the notes will
    continue to be convertible through and including
    September&#160;30, 2008.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Generally, upon conversion of a note, we must pay the conversion
    value of the note in cash, up to the principal amount of the
    note. Any excess of the conversion value over the principal
    amount is payable in shares of our common stock. We currently do
    not have sufficient cash to pay the cash amounts that would be
    due, based on current stock prices, if all the notes were
    converted. However, as was the case during the second calendar
    quarter of 2008, the notes currently continue to trade above
    their conversion value. As a result, we do not currently expect
    any notes to be converted during the third calendar quarter of
    2008. Holders of the notes may nonetheless convert their notes
    during this period.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    If a significant amount of the notes are tendered for
    conversion, we may have to seek additional financing to satisfy
    our conversion obligation. We may be unable to obtain any needed
    additional financing on favorable terms, if at all. In addition,
    if we raise funds by issuing additional equity securities, our
    existing stockholders may experience dilution. Additional debt
    financing, if available, may subject us to restrictive covenants
    and will increase our interest expense. If we fail to deliver
    the consideration that is due upon conversion when required, we
    will be in default under the indenture for the notes, which may
    permit the noteholders to cause the notes to be immediately
    payable in full.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;We
    could lose the tax deduction on our outstanding convertible
    notes.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We could lose some or all of the tax deduction for interest
    expense associated with our $400.0&#160;million 0.625%
    convertible senior notes due February 2014 if the foregoing
    notes are not subject to the special Treasury Regulations
    governing integration of certain debt instruments, which we do
    not expect to be the case, the notes are converted, or we invest
    in non-taxable investments.
</DIV>

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">Risks Related to
    Our Common Stock</FONT></B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;Our
    poison pill, provisions of our charter documents and Delaware
    General Corporation Law may deter or prevent a business
    combination that may be favorable to you.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Provisions of our charter documents could deter or prevent a
    third party from acquiring us, even if doing so would be
    beneficial to our stockholders. These provisions include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="3%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    establishing a classified board of directors, so that only a
    portion of our total board can be elected at each annual meeting;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    setting limitations on the removal of our directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    granting our board of directors the authority to issue
    &#147;blank check&#148; preferred stock without stockholder
    approval;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    prohibiting cumulative voting in the election of our directors,
    which would permit less than a majority of stockholders to elect
    our directors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    limiting our stockholders&#146; ability to call special
    meetings;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    prohibiting stockholder action by written consent.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We have also established a rights agreement, also called a
    &#147;poison pill.&#148; Generally, our rights agreement permits
    our existing stockholders to purchase a large number of our
    shares at a substantial discount to the market price if a third
    party attempts to gain control of a sufficient equity position
    in us. Our rights agreement could have the effect of deterring
    or preventing a third party from acquiring us in a transaction
    that might be favorable to you.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    In addition, Section&#160;203 of the Delaware General
    Corporation Law generally prohibits us, for a period of three
    years, from engaging in any business combination with certain
    persons who own 15%
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-14
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    or more of our outstanding voting stock or any of our associates
    or affiliates who at any time in the past three years have owned
    15% or more of our outstanding voting stock. These provisions
    could adversely affect the price that investors are willing to
    pay for shares of our common stock and could prevent you from
    realizing any premium that stockholders may otherwise receive in
    connection with a corporate takeover.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;We
    may invest or spend the proceeds of this offering in ways with
    which you may not agree and that may not earn a return for our
    stockholders.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We will retain broad discretion over the use of the proceeds
    from this offering. You may not agree with the way we decide to
    use those proceeds, and our use of the proceeds may not yield a
    significant return or any return at all for our stockholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;We
    do not intend to pay cash dividends on our common stock in the
    foreseeable future.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We have not declared or paid any cash dividends on our common
    stock or other securities, and we currently do not anticipate
    paying any cash dividends in the foreseeable future.
    Accordingly, our stockholders will not realize a return on their
    investment unless the trading price of our common stock
    appreciates. Our common stock may not appreciate in value after
    this offering and may not even maintain the price at which you
    purchased your shares.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;Market
    volatility may affect our stock price, and the value of your
    investment in our common stock may experience sudden
    decreases.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    There has been, and will likely continue to be, significant
    volatility in the market price of securities of life sciences
    and biotechnology companies, including us. These fluctuations
    can be unrelated to the operating performance of these
    companies. During the period from January&#160;1, 2006 to
    August&#160;1, 2008, the lowest and highest reported trading
    prices of our common stock on The NASDAQ Global Select Market
    were $13.75 and $95.75, respectively. Factors such as the
    following could cause the market price of our common stock to
    fluctuate substantially:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="3%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    announcements of new products or services by us or our
    competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    litigation involving or affecting us;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    quarterly fluctuations in our or other companies&#146; financial
    results;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    shortfalls in our actual financial results compared to our
    guidance or the forecasts of stock market analysts;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    acquisitions or strategic alliances by us or our competitors;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    the gain or loss of a significant customer;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    general conditions in our industry and in the financial markets.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    A decline in the market price of our common stock could cause
    you to lose some or all of your investment and may adversely
    impact our ability to attract and retain employees, acquire
    other companies or businesses and raise capital. In addition,
    stockholders may initiate securities class action lawsuits if
    the market price of our stock drops significantly, which may
    cause us to incur substantial costs and could divert the time
    and attention of our management.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><I><FONT style="font-family: Arial, Helvetica">&#160;&#160;Investors
    in this offering will pay a much higher price than the book
    value of our common stock.</FONT></I></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The offering price of our common stock will be substantially
    higher than the net tangible book value of our common stock
    immediately after the offering. As a result, purchasers of our
    common stock in this offering will incur immediate and
    substantial dilution. Those purchasers could experience
    additional dilution upon the exercise of outstanding stock
    options and warrants.
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-15
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='104'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">SPECIAL
    NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    This prospectus supplement and the accompanying prospectus,
    including the documents that we incorporate by reference,
    contain forward-looking statements within the meaning of
    Section&#160;27A of the Securities Act of 1933, as amended, and
    within the meaning of Section&#160;21E of the Securities
    Exchange Act of 1934, as amended, that are subject to the
    &#147;safe harbor&#148; created by those sections.
    Forward-looking statements include statements about our
    expectations, beliefs, plans, objectives, intentions,
    assumptions and other statements that are not historical facts.
    Words or phrases such as &#147;anticipate,&#148;
    &#147;believe,&#148; &#147;continue,&#148; &#147;ongoing,&#148;
    &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148;
    &#147;may,&#148; &#147;plan,&#148; &#147;potential,&#148;
    &#147;predict,&#148; &#147;project&#148; or similar words or
    phrases, or the negatives of those words or phrases, may
    identify forward-looking statements, but the absence of these
    words does not necessarily mean that a statement is not
    forward-looking.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Examples of forward-looking statements include, among others,
    the commercial launch of new products and the duration which our
    existing cash and other resources is expected to fund our
    operating activities.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Forward-looking statements are subject to known and unknown
    risks and uncertainties and are based on potentially inaccurate
    assumptions that could cause actual results to differ materially
    from those expected or implied by the forward-looking
    statements. Our actual results could differ materially from
    those anticipated in forward-looking statements for many
    reasons, including the factors described in the section titled
    &#147;Risk Factors&#148; in this prospectus supplement.
    Accordingly, you should not unduly rely on these forward-looking
    statements, which speak only as of the date of the document in
    which they are contained. Except as required by law, we
    undertake no obligation to publicly revise any forward-looking
    statement to reflect circumstances or events after the date of
    this prospectus supplement or to reflect the occurrence of
    unanticipated events. You should, however, review the factors
    and risks we describe in the reports we file from time to time
    with the SEC. See &#147;Where You Can Find More
    Information.&#148;
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-16
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='105'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">USE OF
    PROCEEDS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We estimate that the net proceeds from the sale of the
    3,500,000&#160;shares of common stock we are offering will be
    approximately $297.9&#160;million, at a public offering price of
    $87.50 per share and after deducting underwriting discounts and
    commissions and the estimated offering expenses payable by us.
    If the underwriter exercises its option to purchase additional
    shares in full, we estimate the net proceeds to us will be
    approximately $342.6&#160;million.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We intend to use the net proceeds from this offering to fund
    research and development, to continue expanding our
    manufacturing capacity as required and to provide for working
    capital needs. We may also use a portion of the net proceeds to
    acquire, license or invest in complementary businesses,
    technologies or products. While we evaluate acquisition,
    licensing, investment and similar opportunities and engage in
    related discussions from time to time, we currently have no
    material agreements or commitments with respect to any such
    acquisition, license or investment.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Although we have identified some of the potential uses of the
    proceeds from this offering, we have and reserve broad
    discretion in the application of these proceeds. Accordingly, we
    reserve the right to use these proceeds for different purposes
    or uses which we have not listed above.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Pending any ultimate use of any portion of the proceeds from
    this offering, we intend to invest the proceeds in a variety of
    capital preservation investments, which may include short-term,
    interest-bearing instruments.
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-17
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='106'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">PRICE RANGE OF
    OUR COMMON STOCK</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Our common stock is traded publicly on The NASDAQ Global Select
    Market under the symbol &#147;ILMN.&#148; The following table
    presents quarterly information on the price range of our common
    stock. This information indicates the high and low sales prices
    reported by The NASDAQ Global Select Market. These prices do not
    include retail markups, markdowns or commissions.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-size: 10pt">High</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="right" valign="bottom">
    <B><FONT style="font-size: 10pt">Low</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="8" align="right" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Calendar Year Ended December&#160;31, 2006</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    First Calendar Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;27.98
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;&#160;&#160;&#160;13.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Second Calendar Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    21.60
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Third Calendar Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40.00
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    27.02
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fourth Calendar Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    45.87
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    32.20
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Calendar Year Ended December&#160;31, 2007</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    First Calendar Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    42.19
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    28.11
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Second Calendar Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    42.08
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    28.94
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Third Calendar Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    53.88
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    40.04
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Fourth Calendar Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    63.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    50.34
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <B>Calendar Year Ended December&#160;31, 2008</B>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    First Calendar Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    77.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    55.77
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Second Calendar Quarter
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    90.38
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    69.80
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 20pt">
    Third Calendar Quarter (through August&#160;6, 2008)
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    95.75
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    82.66
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    As of July&#160;28, 2008, there were approximately 574 holders
    of record of our common stock. On August&#160;6, 2008, the last
    sale price reported on The NASDAQ Global Select Market for our
    common stock was $89.25 per share.
</DIV>
<A name='107'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">DIVIDEND
    POLICY</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We have never declared or paid any cash dividends on our common
    stock. We currently intend to retain all of our future earnings,
    if any, to finance operations, and we do not anticipate paying
    cash dividends in the foreseeable future.
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-18
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='108'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">CAPITALIZATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The following table sets forth our cash, cash equivalents,
    short-term investments and capitalization as of June&#160;29,
    2008:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="3%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    on an actual basis;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    on an adjusted basis to give effect to the sale of
    3,500,000&#160;shares of our common stock we are offering at a
    public offering price of $87.50, after deducting underwriting
    discounts and commissions and estimated offering expenses to be
    paid by us.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 9pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="75%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="1%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="8%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom" style="border-bottom: 1px solid #000000">
    <B>As of June&#160;29, 2008</B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">Actual</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
    <B><FONT style="font-size: 9pt">As adjusted</FONT></B>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 1pt" valign="bottom" align="center">
<TD colspan="8" align="center" valign="bottom" style="font-size: 1pt; border-bottom: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="font-size: 9pt" valign="bottom" align="center">
<TD nowrap align="left" valign="bottom">
    (in thousands, except share and per share data)
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="6" align="center" valign="bottom">
    (unaudited)
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Cash, cash equivalents and short-term investments
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    &#160;&#160;303,275
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    601,125
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    0.625%&#160;Convertible Senior Notes due
    2014<SUP style="font-size: 85%; vertical-align: text-top">(1)</SUP>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    400,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    400,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Long-term obligations, less current portion
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    14,885
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Stockholders&#146; equity:
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Preferred stock, $0.01&#160;par value per share;
    10,000,000&#160;shares authorized; no shares issued and
    outstanding, actual and as adjusted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    &#151;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Common stock, $0.01&#160;par value per share;
    120,000,000&#160;shares authorized; 64,553,019&#160;shares
    issued and outstanding (including treasury shares), actual;
    68,053,019&#160;shares issued and outstanding (including
    treasury shares), as adjusted
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    646
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    681
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Additional paid in capital
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,097,619
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    1,395,434
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Accumulated other comprehensive loss
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (739
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (739
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Accumulated deficit
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (354,152
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (354,152
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 18pt">
    Treasury stock, at cost; 7,409,545&#160;shares
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (251,622
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    (251,622
</TD>
<TD nowrap align="left" valign="bottom">
    )
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="background: #CCEEFF">
<TD align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 27pt">
    Total stockholders&#146; equity
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    491,752
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    789,602
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD style="border-top: 1px solid #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -9pt; margin-left: 9pt">
    Total capitalization
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    506,637
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    804,487
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom" style="font-size: 1pt">
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD style="border-top: 3px double #000000">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV style="font-size: 1pt; margin-left: 0%; width: 13%;  align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=455 length=60 -->

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>



<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

<TR>
    <TD width="1%"></TD>
    <TD width="1%"></TD>
    <TD width="98%"></TD>
</TR>

<TR>
    <TD align="right" valign="top">
    <I><FONT style="font-size: 8pt">(1) </FONT></I></TD>
    <TD></TD>
    <TD valign="bottom">
    <I><FONT style="font-size: 8pt">Our convertible notes were
    classified as a current liability as of June&#160;29,
    2008.</FONT></I></TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The table above should be read in conjunction with our
    consolidated financial statements and related notes incorporated
    by reference in this prospectus supplement. This table is based
    on 64,553,019&#160;shares of our common stock outstanding as of
    June&#160;29, 2008, including 7,409,545&#160;shares held in
    treasury, and excludes:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="3%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    9,662,777&#160;shares of our common stock issuable upon exercise
    of options outstanding as of June&#160;29, 2008, at a weighted
    average exercise price of 30.45 per share;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    10,748,961&#160;shares of our common stock issuable upon
    exercise of warrants outstanding as of June&#160;29, 2008, at a
    weighted average exercise price of 56.54 per share;
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    3,730,108&#160;shares of our common stock available for future
    grant under our equity incentive plans as of June&#160;29,
    2008;&#160;and
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    up to 9,161,160&#160;shares of our common stock, subject to
    adjustment, issuable upon conversion of our outstanding
    convertible notes.
</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-19
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='109'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">UNDERWRITING</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The company and Goldman, Sachs &#038; Co. have entered into an
    underwriting agreement with respect to the shares being offered.
    Subject to certain conditions, the underwriter has agreed to
    purchase the number of shares indicated on the cover of this
    prospectus supplement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The underwriter is committed to take and pay for all of the
    shares being offered, if any are taken, other than the shares
    covered by the option described below unless and until this
    option is exercised.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    If the underwriter sells more shares than the total number set
    forth on the cover of this prospectus supplement, it has an
    option to buy up to an additional 525,000&#160;shares from the
    company. It may exercise that option for 30&#160;days.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The following tables show the per share and total underwriting
    discounts and commissions to be paid to the underwriter by the
    company. Such amounts are shown assuming both no exercise and
    full exercise of the underwriter&#146;s option to purchase
    525,000 additional shares.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
<!-- Table Width Row BEGIN -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="72%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="2%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=02 type=lead -->
    <TD width="9%" align="right">&nbsp;</TD>	<!-- colindex=02 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=02 type=hang1 -->
    <TD width="3%">&nbsp;</TD>	<!-- colindex=03 type=gutter -->
    <TD width="1%" align="right">&nbsp;</TD>	<!-- colindex=03 type=lead -->
    <TD width="10%" align="right">&nbsp;</TD>	<!-- colindex=03 type=body -->
    <TD width="1%" align="left">&nbsp;</TD>	<!-- colindex=03 type=hang1 -->
</TR>
<!-- Table Width Row END -->
<TR style="font-size: 8pt" valign="bottom" align="center">
<TD nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <FONT style="font-size: 10pt">Paid by the Company
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <FONT style="font-size: 10pt">No Exercise
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD colspan="2" nowrap align="center" valign="bottom">
<DIV style="border-bottom: 1px solid #000000; width: 1%; padding-bottom: 1px">
    <FONT style="font-size: 10pt">Full Exercise
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
</TR>
<TR style="line-height: 3pt; font-size: 1pt">
<TD>&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Per share
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    2.30
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    Total
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    8,050,000
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="left" valign="bottom">
    $
</TD>
<TD nowrap align="right" valign="bottom">
    9,257,500
</TD>
<TD nowrap align="left" valign="bottom">
&nbsp;
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Shares sold by the underwriter to the public will initially be
    offered at the initial public offering price set forth on the
    cover of this prospectus supplement. Any shares sold by the
    underwriter to securities dealers may be sold at a discount of
    up to $1.38 per share from the initial public offering price. If
    all the shares are not sold at the initial public offering
    price, the underwriter may change the offering price and the
    other selling terms. The offering of the shares by the
    underwriter is subject to receipt and acceptance and subject to
    the underwriter&#146;s right to reject any order in whole or in
    part.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The company and certain of its directors and officers have
    agreed with the underwriter, subject to certain exceptions, not
    to dispose of or hedge any of their common stock or securities
    convertible into or exchangeable for shares of common stock
    during the period from the date of this prospectus supplement
    continuing through the date 90&#160;days after the date of this
    prospectus supplement, except with the prior written consent of
    the underwriter. This agreement does not apply to shares
    issuable upon conversion, exchange or exercise of convertible,
    exchangeable or exercisable securities outstanding as of the
    date of this prospectus supplement or under any existing
    employee benefit plans or to shares subject to certain
    <FONT style="white-space: nowrap">Rule&#160;10b5-1</FONT>
    plans.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    In connection with the offering, the underwriter may purchase
    and sell shares of common stock in the open market. These
    transactions may include short sales, stabilizing transactions
    and purchases to cover positions created by short sales. Shorts
    sales involve the sale by the underwriter of a greater number of
    shares than it is required to purchase in the offering.
    &#147;Covered&#148; short sales are short sales made in an
    amount not greater than the underwriter&#146;s option to
    purchase additional shares from the company in the offering. The
    underwriter may close out any covered short position by either
    exercising its option to purchase additional shares or
    purchasing shares in the open market. In determining the source
    of shares to close out the covered short position, the
    underwriter will consider, among other things, the price of
    shares available for purchase in the open market as compared to
    the price at which it may purchase additional shares pursuant to
    the option granted to it. &#147;Naked&#148; short sales are any
    short sales in excess of such option. The underwriter must close
    out any naked short position by purchasing shares in the open
    market. A naked short position is more likely to be created if
    the underwriter is concerned that there may be downward pressure
    on the price of the common stock in the open market after
    pricing that could adversely affect investors who purchase in
    the offering. Stabilizing transactions consist of various bids
    for or purchases of common stock made by the underwriter in the
    open market prior to the completion of the offering.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Purchases to cover a short position and stabilizing
    transactions, as well as other purchases by the underwriter for
    its own account, may have the effect of preventing or retarding
    a decline in the market price of the company&#146;s stock, and
    may stabilize, maintain or otherwise affect the market price of
    the
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-20
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    common stock. As a result, the price of the common stock may be
    higher than the price that otherwise might exist in the open
    market. If these activities are commenced, they may be
    discontinued at any time. These transactions may be effected on
    The NASDAQ Global Select Market, in the over-the-counter market
    or otherwise.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    In relation to each Member State of the European Economic Area
    which has implemented the Prospectus Directive (each, a Relevant
    Member State), the underwriter has represented and agreed that
    with effect from and including the date on which the Prospectus
    Directive is implemented in that Relevant Member State (the
    Relevant Implementation Date) it has not made and will not make
    an offer of shares to the public in that Relevant Member State
    prior to the publication of a prospectus in relation to the
    shares which has been approved by the competent authority in
    that Relevant Member State or, where appropriate, approved in
    another Relevant Member State and notified to the competent
    authority in that Relevant Member State, all in accordance with
    the Prospectus Directive, except that it may, with effect from
    and including the Relevant Implementation Date, make an offer of
    shares to the public in that Relevant Member State at any time:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="4%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (a)&#160;
</TD>
    <TD align="left">
    to legal entities which are authorized or regulated to operate
    in the financial markets or, if not so authorized or regulated,
    whose corporate purpose is solely to invest in securities;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (b)&#160;
</TD>
    <TD align="left">
    to any legal entity which has two or more of (1)&#160;an average
    of at least 250&#160;employees during the last financial year;
    (2)&#160;a total balance sheet of more than &#128;43,000,000 and
    (3)&#160;an annual net turnover of more than &#128;50,000,000,
    as shown in its last annual or consolidated accounts;
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (c)&#160;
</TD>
    <TD align="left">
    to fewer than 100 natural or legal persons (other than qualified
    investors as defined in the Prospectus Directive) subject to
    obtaining the prior consent of the underwriter for any such
    offer;&#160;or
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (d)&#160;
</TD>
    <TD align="left">
    in any other circumstances which do not require the publication
    by the Issuer of a prospectus pursuant to Article&#160;3 of the
    Prospectus Directive.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    For the purposes of this provision, the expression an
    &#147;offer of shares to the public&#148; in relation to any
    shares in any Relevant Member State means the communication in
    any form and by any means of sufficient information on the terms
    of the offer and the shares to be offered so as to enable an
    investor to decide to purchase or subscribe for the shares, as
    the same may be varied in that Relevant Member State by any
    measure implementing the Prospectus Directive in that Relevant
    Member State, and the expression Prospectus Directive means
    Directive 2003/71/EC and includes any relevant implementing
    measure in each Relevant Member State.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The underwriter has represented and agreed that:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="4%"></TD>
    <TD width="94%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (a)&#160;
</TD>
    <TD align="left">
    it has only communicated or caused to be communicated and will
    only communicate or cause to be communicated an invitation or
    inducement to engage in investment activity (within the meaning
    of Section&#160;21 of the FSMA) received by it in connection
    with the issue or sale of the shares in circumstances in which
    Section&#160;21(1) of the FSMA does not apply to the
    Issuer;&#160;and
</TD>
</TR>


<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    (b)&#160;
</TD>
    <TD align="left">
    it has complied and will comply with all applicable provisions
    of the FSMA with respect to anything done by it in relation to
    the shares in, from or otherwise involving the United Kingdom.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The shares may not be offered or sold by means of any document
    other than (i)&#160;in circumstances which do not constitute an
    offer to the public within the meaning of the Companies
    Ordinance (Cap.32, Laws of Hong Kong), or (ii)&#160;to
    &#147;professional investors&#148; within the meaning of the
    Securities and Futures Ordinance (Cap.571, Laws of Hong Kong)
    and any rules made thereunder, or (iii)&#160;in other
    circumstances which do not result in the document being a
    &#147;prospectus&#148; within the meaning of the Companies
    Ordinance (Cap.32, Laws of Hong Kong), and no advertisement,
    invitation or document relating to the shares may be issued or
    may be in the possession of any person for the purpose of issue
    (in each case whether in Hong Kong or elsewhere), which is
    directed at, or the contents of which are likely to be accessed
    or read by, the public in Hong Kong (except if permitted to do
    so under the laws of Hong Kong) other than with respect to
    shares which are or are intended to be
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-21
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    disposed of only to persons outside Hong Kong or only to
    &#147;professional investors&#148; within the meaning of the
    Securities and Futures Ordinance (Cap. 571, Laws of Hong Kong)
    and any rules made thereunder.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    This prospectus has not been registered as a prospectus with the
    Monetary Authority of Singapore. Accordingly, this prospectus
    and any other document or material in connection with the offer
    or sale, or invitation for subscription or purchase, of the
    shares may not be circulated or distributed, nor may the shares
    be offered or sold, or be made the subject of an invitation for
    subscription or purchase, whether directly or indirectly, to
    persons in Singapore other than (i)&#160;to an institutional
    investor under Section&#160;274 of the Securities and Futures
    Act, Chapter&#160;289 of Singapore (the &#147;SFA&#148;),
    (ii)&#160;to a relevant person, or any person pursuant to
    Section&#160;275(1A), and in accordance with the conditions,
    specified in Section&#160;275 of the SFA or (iii)&#160;otherwise
    pursuant to, and in accordance with the conditions of, any other
    applicable provision of the SFA.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Where the shares are subscribed or purchased under
    Section&#160;275 by a relevant person which is: (a)&#160;a
    corporation (which is not an accredited investor) the sole
    business of which is to hold investments and the entire share
    capital of which is owned by one or more individuals, each of
    whom is an accredited investor; or (b)&#160;a trust (where the
    trustee is not an accredited investor) whose sole purpose is to
    hold investments and each beneficiary is an accredited investor,
    shares, debentures and units of shares and debentures of that
    corporation or the beneficiaries&#146; rights and interest in
    that trust shall not be transferable for 6&#160;months after
    that corporation or that trust has acquired the shares under
    Section&#160;275 except: (1)&#160;to an institutional investor
    under Section&#160;274 of the SFA or to a relevant person, or
    any person pursuant to Section&#160;275(1A), and in accordance
    with the conditions specified in Section&#160;275 of the SFA;
    (2)&#160;where no consideration is given for the transfer; or
    (3)&#160;by operation of law.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The securities have not been and will not be registered under
    the Financial Instruments and Exchange Law of Japan (the
    Securities and Exchange Law) and the underwriter has agreed that
    it will not offer or sell any securities, directly or
    indirectly, in Japan or to, or for the benefit of, any resident
    of Japan (which term as used herein means any person resident in
    Japan, including any corporation or other entity organized under
    the laws of Japan), or to others for re-offering or resale,
    directly or indirectly, in Japan or to a resident of Japan,
    except pursuant to an exemption from the registration
    requirements of, and otherwise in compliance with, the Financial
    Instruments and Exchange Law and any other applicable laws,
    regulations and ministerial guidelines of Japan.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The company estimates that the total expenses of the offering,
    excluding underwriting discounts and commissions, will be
    approximately $350,000.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    In compliance with FINRA guidelines, the maximum compensation to
    any underwriters or agents in connection with the sale of any
    securities pursuant to this prospectus supplement and the
    accompanying prospectus will not exceed 8% of the aggregate
    total offering price to the public of such securities as set
    forth on the cover of this prospectus supplement; however, it is
    anticipated that the maximum compensation paid will be
    significantly less than 8%.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The company has agreed to indemnify the underwriter against
    certain liabilities, including liabilities under the Securities
    Act of 1933.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The underwriter and its affiliates have, from time to time,
    performed, and may in the future perform, various financial
    advisory and investment banking services for the company, for
    which they received or will receive customary fees and expenses.
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-22
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='110'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">WHERE YOU CAN
    FIND MORE INFORMATION</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We file annual, quarterly and current reports, proxy statements
    and other information with the SEC. Our SEC filings are
    available to the public over the Internet at the SEC&#146;s
    website at
    <FONT style="white-space: nowrap">http://www.sec.gov.</FONT>
    The SEC&#146;s website contains reports, proxy and information
    statements and other information regarding issuers, such as us,
    that file electronically with the SEC. You may also read and
    copy any document we file with the SEC at the SEC&#146;s Public
    Reference Room at 100&#160;F&#160;Street, N.E., Room&#160;1580,
    Washington,&#160;D.C. 20549. You may also obtain copies of these
    documents at prescribed rates by writing to the SEC. Please call
    the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330</FONT>
    for further information on the operation of its Public Reference
    Room. We maintain a website at
    <FONT style="white-space: nowrap">http://www.illumina.com.</FONT>
    We have not incorporated by reference into this prospectus
    supplement or the accompanying prospectus the information in, or
    that can be accessed through, our website, and you should not
    consider it to be a part of this prospectus supplement or the
    accompanying prospectus.
</DIV>

<DIV style="margin-top: 9pt; font-size: 1pt">&nbsp;</DIV>
<A name='111'>
<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">INCORPORATION OF
    CERTAIN DOCUMENTS BY REFERENCE</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The SEC allows us to &#147;incorporate by reference&#148; into
    this prospectus supplement the information we have filed with
    the SEC. The information we incorporate by reference into this
    prospectus supplement is an important part of this prospectus
    supplement. Any statement in a document we have filed with the
    SEC prior to the date of this prospectus supplement or the
    accompanying prospectus and which is incorporated by reference
    into this prospectus supplement or the accompanying prospectus
    will be considered to be modified or superseded to the extent a
    statement contained in this prospectus supplement, the
    accompanying prospectus or any other subsequently filed document
    that is incorporated by reference into this prospectus
    supplement modifies or supersedes that statement. The modified
    or superseded statement will not be considered to be a part of
    this prospectus supplement or accompanying prospectus, as
    applicable, except as modified or superseded.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    We incorporate by reference into this prospectus supplement the
    information contained in the documents listed below, which is
    considered to be a part of this prospectus supplement:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="2%"></TD>
    <TD width="3%"></TD>
    <TD width="95%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    our annual report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended December&#160;30, 2007, filed with the
    SEC on February&#160;26, 2008 (file
    <FONT style="white-space: nowrap">no.&#160;000-30361);</FONT>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    our quarterly reports filed on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the fiscal quarters ended March&#160;30, 2008 and
    June&#160;29, 2008, filed with the SEC on April&#160;28, 2008
    and July&#160;25, 2008, respectively (file
    <FONT style="white-space: nowrap">no.&#160;000-30361);</FONT>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    our current reports on
    <FONT style="white-space: nowrap">Form&#160;8-K,</FONT>
    excluding the portions that were &#147;furnished&#148; in
    accordance with SEC rules, as filed with the SEC on
    January&#160;4, 2008, January&#160;15, 2008, March&#160;17,
    2008, March&#160;25, 2008, March&#160;26, 2008, April&#160;17,
    2008, May&#160;19, 2008 and June&#160;17, 2008 (file
    <FONT style="white-space: nowrap">no.&#160;000-30361);</FONT>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    the description of our common stock contained in our
    registration statement on
    <FONT style="white-space: nowrap">Form&#160;8-A,</FONT>
    filed with the SEC on April&#160;14, 2000, including any
    amendments or reports filed for the purpose of updating such
    description (file
    <FONT style="white-space: nowrap">no.&#160;000-30361);</FONT>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    the description of our preferred stock purchase rights contained
    in our registration statement on
    <FONT style="white-space: nowrap">Form&#160;8-A,</FONT>
    filed with the SEC on May&#160;14, 2001, including any
    amendments or reports filed for the purpose of updating such
    description (file
    <FONT style="white-space: nowrap">no.&#160;000-30361);&#160;and</FONT>
</TD>
</TR>


<TR style="line-height: 3pt; font-size: 1pt"><TD>&nbsp;</TD></TR>


<TR valign="top" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <TD>&nbsp;</TD>
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">
    future filings we make with the SEC under Sections&#160;13(a),
    13(c), 14, or 15(d) of the Exchange Act after the date of this
    prospectus supplement but prior to the termination of the
    offering of the securities covered by this prospectus supplement
    and the accompanying prospectus.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    You may request a copy of these filings, at no cost, by writing
    or telephoning us at the following address:
</DIV>



<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: Arial, Helvetica">Illumina, Inc.<BR>
    9885 Towne Centre Drive<BR>
    San&#160;Diego, California 92121<BR>
    <FONT style="white-space: nowrap">(858)&#160;202-4500</FONT>
    </FONT>
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-23
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->
<A name='112'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">LEGAL
    MATTERS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    The validity of the shares of common stock offered by this
    prospectus supplement will be passed upon for us by
    Dewey&#160;&#038; LeBoeuf LLP, New York, NY, and for the
    underwriter by Sullivan&#160;&#038; Cromwell LLP, Los Angeles,
    CA.
</DIV>
<A name='113'>
<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: Arial, Helvetica">EXPERTS</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 2%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    Ernst&#160;&#038; Young LLP, independent registered public
    accounting firm, has audited our consolidated financial
    statements and schedule included in our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended December&#160;30, 2007, and the effectiveness
    of our internal control over financial reporting as of
    December&#160;30, 2007, as set forth in their reports, which are
    incorporated by reference in this prospectus supplement and
    elsewhere in the registration statement. Our financial
    statements and schedule are incorporated by reference in
    reliance on Ernst&#160;&#038; Young LLP&#146;s reports, given on
    their authority as experts in accounting and auditing.
</DIV>

<P align="center" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <BR>
    S-24
</DIV><!-- END PAGE WIDTH -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->
<A name='119'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <FONT style="font-family: 'Times New Roman', Times">PROSPECTUS
    </FONT>
</DIV>

<DIV style="font-size: 3pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 15pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <IMG src="a42519fz4251903.gif" alt="(ILLUMINA LOGO)" ><FONT style="font-size: 8pt">
    </FONT>
</DIV>

<DIV style="margin-top: 15pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B><I><FONT style="font-size: 12pt">Common Stock</FONT></I></B>
</DIV>

<DIV style="margin-top: 15pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 18pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may offer to sell shares of our common stock from time to
    time in one or more offerings. This prospectus describes some of
    the general terms that may apply to an offering of our common
    stock. We will describe the details of each offering, including
    the number of shares offered and the offering price, in a
    post-effective amendment to the registration statement of which
    this prospectus is a part, in one or more supplements to this
    prospectus or in one or more documents incorporated by reference
    into this prospectus.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may offer and sell common stock to or through one or more
    underwriters, dealers or agents, directly to purchasers or
    otherwise.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our common stock is quoted on the Nasdaq National Market under
    the symbol &#147;ILMN.&#148;
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Investing in our common stock involves a high degree of risk.
    Before buying any shares you should read the discussion of
    material risks of investing in our common stock in &#147;Risk
    Factors&#148; beginning on page&#160;2.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <B>Neither the Securities and Exchange Commission nor any state
    securities commission has approved or disapproved of these
    securities or passed upon the adequacy or accuracy of this
    prospectus. Any representation to the contrary is a criminal
    offense.</B>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The date of this prospectus is May&#160;11, 2006.
</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV style="font-size: 0pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">TABLE OF
    CONTENTS</FONT></B>
</DIV>

<DIV style="font-size: 2pt; margin-left: 0%; width: 100%; align: left; border-bottom: 1pt solid #000000"></DIV><!-- callerid=999 iwidth=456 length=0 -->

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>



<TABLE border="0" width="100%" align="center" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
<!-- Table Width Row -->
<TR style="font-size: 1pt" valign="bottom">
    <TD width="92%">&nbsp;</TD>	<!-- colindex=01 type=maindata -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=gutter -->
    <TD width="4%">&nbsp;</TD>	<!-- colindex=02 type=maindata -->
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#120'><FONT style="font-size: 10pt">About this
    Prospectus</A>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-size: 10pt">1</FONT></B>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#121'><FONT style="font-size: 10pt">Risk Factors</A>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-size: 10pt">2</FONT></B>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#122'><FONT style="font-size: 10pt">Use of Proceeds</A>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-size: 10pt">9</FONT></B>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#123'><FONT style="font-size: 10pt">Where You Can Find
    More Information</A>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-size: 10pt">9</FONT></B><FONT style="font-size: 10pt">
    </FONT>
</TD>
</TR>
<TR valign="bottom">
<TD align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#124'><FONT style="font-size: 10pt">Incorporation of
    Certain Documents by Reference</A>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-size: 10pt">9</FONT></B>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#125'><FONT style="font-size: 10pt">Legal Matters</A>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-size: 10pt">10</FONT></B>
</TD>
</TR>
<TR valign="bottom">
<TD nowrap align="left" valign="bottom">
<DIV style="text-indent: -10pt; margin-left: 10pt">
    <A HREF='#126'><FONT style="font-size: 10pt">Experts</A>
    </FONT>
</DIV>
</TD>
<TD>
&nbsp;
</TD>
<TD nowrap align="right" valign="bottom">
    <B><FONT style="font-size: 10pt">10</FONT></B><FONT style="font-size: 10pt">
    </FONT>
</TD>
</TR>
</TABLE>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV>

<P align="left" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">

</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='120'><B><FONT style="font-size: 14pt">About this
    Prospectus</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus is part of a registration statement that we have
    filed with the Securities and Exchange Commission using the
    &#147;shelf&#148; registration process. By using a shelf
    registration statement, we may offer and sell our common stock
    from time to time in one or more offerings. There is no limit on
    the number of shares of common stock we may sell pursuant to the
    registration statement.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You should rely only on the information contained in or
    incorporated by reference into this prospectus and any
    applicable prospectus supplement and the information contained
    in any permitted free writing prospectuses we have authorized
    for use with respect to the applicable offering. We have not
    authorized anyone to provide you with different or additional
    information. This document may only be used where it is legal to
    sell our common stock. You should not assume that the
    information contained in this prospectus, any prospectus
    supplement or any related permitted free writing prospectus we
    have authorized is accurate as of any date other than its date,
    regardless of when you receive those documents or when any
    particular sale of our common stock occurs.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    This prospectus and the information incorporated by reference
    into this prospectus includes trademarks, service marks and
    trade names owned by us or others. All trademarks, service marks
    and trade names included or incorporated by reference in this
    prospectus are the property of their respective owners.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Unless the context requires otherwise, the words
    &#147;Illumina,&#148; &#147;we,&#148; &#147;company,&#148;
    &#147;us&#148; and &#147;our&#148; refer to Illumina, Inc. and
    its subsidiaries, and the term &#147;you&#148; refers to a
    prospective investor. Our principal executive offices are
    located at 9885&#160;Towne Centre Drive, San&#160;Diego,
    California 92121. Our phone number is
    <FONT style="white-space: nowrap">(858)&#160;202-4500.</FONT>
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    1
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <A name='121'><B><FONT style="font-size: 14pt">Risk
    Factors</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <I>Investing in our common stock involves a high degree of risk.
    In addition to the other information included and incorporated
    by reference in this prospectus or accompanying prospectus
    supplement or in any free writing prospectus we have authorized,
    you should carefully consider the risks described below before
    purchasing our common stock. If any of the following risks
    actually occurs, our business, results of operations and
    financial condition will likely suffer. As a result, the trading
    price of our common stock may decline, and you might lose part
    or all of your investment.</I>
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RISKS
    RELATED TO OUR BUSINESS</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Litigation
    or other proceedings or third party claims of intellectual
    property infringement could require us to spend significant time
    and money and could prevent us from selling our products or
    services or impact our stock price.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our commercial success depends in part on our non-infringement
    of the patents or proprietary rights of third parties and the
    ability to protect our own intellectual property. As described
    in our Quarterly Report on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the quarter period ended April&#160;2, 2006, filed with the
    SEC on May&#160;8, 2006, under the caption &#147;Part&#160;II.
    Other Information. Item&#160;1. Legal Proceedings,&#148;
    Affymetrix, Inc. filed a complaint against us in July 2004,
    alleging infringement of six of its patents.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    On April&#160;20, 2006, a claims construction hearing was held
    as part of this proceeding. We expect a ruling related to the
    claims construction within the next several weeks, but there is
    no fixed time for such a ruling. At issue is the meaning of 15
    terms, and depending on the court&#146;s ruling on each of the
    15 terms, or a mix of rulings across all the terms, an advantage
    (or at least the perception of an advantage) may be obtained by
    one party or the other as to one or more issues. We are not able
    to predict the timing or the substance of the court&#146;s
    rulings. Any adverse ruling or perception of an adverse ruling
    may have an adverse impact on our stock price, and such impact
    may be disproportionate to the actual import of the ruling
    itself.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Including Affymetrix, third parties have asserted or may assert
    that we are employing their proprietary technology without
    authorization. As we enter new markets, we expect that
    competitors will likely assert that our products infringe their
    intellectual property rights as part of a business strategy to
    impede our successful entry into those markets. In addition,
    third parties may have obtained and may in the future obtain
    patents and claim that use of our technologies infringes these
    patents. We could incur substantial costs and divert the
    attention of our management and technical personnel in defending
    ourselves against any of these claims. Furthermore, parties
    making claims against us may be able to obtain injunctive or
    other relief, which effectively could block our ability to
    further develop, commercialize and sell products, and could
    result in the award of substantial damages against us. In the
    event of a successful claim of infringement against us, we may
    be required to pay damages and obtain one or more licenses from
    third parties, or be prohibited from selling certain products.
    We may not be able to obtain these licenses at a reasonable
    cost, or at all. We could incur substantial costs related to
    royalty payments for licenses obtained from third parties, which
    could negatively affect our gross margins. In that event, we
    could encounter delays in product introductions while we attempt
    to develop alternative methods or products. Defense of any
    lawsuit or failure to obtain any of these licenses on favorable
    terms could prevent us from commercializing products, and the
    prohibition of sale of any of our products could materially
    affect our ability to grow and to attain profitability.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">We expect
    intense competition in our target markets, which could render
    our products obsolete, result in significant price reductions or
    substantially limit the volume of products that we sell. This
    would limit our ability to compete and achieve and maintain
    profitability. If we cannot continuously develop and
    commercialize new products, our revenue may not grow as
    intended.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We compete with life sciences companies that design, manufacture
    and market instruments for analysis of genetic variation and
    biological function and other applications using technologies
    such as two-dimensional electrophoresis, capillary
    electrophoresis, mass spectrometry, flow cytometry,
    microfluidics, next-generation DNA sequencing and mechanically
    deposited, inkjet and photolithographic arrays. We anticipate
    that we will face increased competition in the future as
    existing companies develop new or improved products and as new
    companies enter the market with new technologies. The markets
    for our products are characterized by rapidly changing
    technology,
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    2
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    evolving industry standards, changes in customer needs, emerging
    competition, new product introductions and strong price
    competition. For example, prices per data point for genotyping
    have fallen significantly over the last two years and we
    anticipate that prices will continue to fall. One or more of our
    competitors may render our technology obsolete or uneconomical.
    Some of our competitors have greater financial and personnel
    resources, broader product lines, a more established customer
    base and more experience in research and development than we do.
    Furthermore, the life sciences and pharmaceutical companies,
    which are our potential customers and strategic partners, could
    develop competing products. If we are unable to develop
    enhancements to our technology and rapidly deploy new product
    offerings, our business, financial condition and results of
    operations will suffer.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    manufacturing capacity may limit our ability to sell our
    products.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are currently ramping up our capacity to meet our anticipated
    demand for our products. Although we have significantly
    increased our manufacturing capacity and we believe that we have
    sufficient plans in place to ensure we have adequate capacity to
    meet our business plan in 2006, there are uncertainties inherent
    in expanding our manufacturing capabilities and we may not be
    able to increase our capacity in a timely manner. For example,
    manufacturing and product quality issues may arise as we
    increase production rates at our manufacturing facility and
    launch new products. As a result, we may experience difficulties
    in meeting customer, collaborator and internal demand, in which
    case we could lose customers or be required to delay new product
    introductions, and demand for our products could decline.
    Additionally, in the past, we have experienced variations in
    manufacturing conditions that have temporarily reduced
    production yields. Due to the intricate nature of manufacturing
    products that contain DNA, we may encounter similar or
    previously unknown manufacturing difficulties in the future that
    could significantly reduce production yields, impact our ability
    to launch or sell these products, or to produce them
    economically, prevent us from achieving expected performance
    levels or cause us to set prices that hinder wide adoption by
    customers.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">We have
    not yet achieved annual operating profitability and may not be
    able to do so.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have incurred net losses each year since our inception. As of
    April&#160;2, 2006, our accumulated deficit was
    $144.7&#160;million and we incurred a net loss of
    $0.1&#160;million for the three months ended April&#160;2, 2006.
    We may not be profitable in 2006, due in part to the impact of
    SFAS&#160;No.&#160;123R, which is expected to add additional
    expense of $12.0&#160;million to $15.0&#160;million in 2006. Our
    ability to achieve annual profitability will depend, in part, on
    the rate of growth, if any, of our revenue and on the level of
    our expenses. We expect to continue incurring significant
    expenses related to research and development, sales and
    marketing efforts to commercialize our products and the
    continued development of our manufacturing capabilities. In
    addition, we expect that our selling and marketing expenses will
    increase at a higher rate in the future as a result of the
    launch of new products. As a result, we expect that our
    operating expenses will increase significantly as we grow and,
    consequently, we will need to generate significant additional
    revenue to achieve and maintain profitability. Even if we
    maintain profitability, we may not be able to increase
    profitability on a quarterly basis.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">The
    growth and profitability of our oligo business depends on a
    third party.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In December 2004, we entered into a collaboration agreement with
    Invitrogen to sell and market our oligos worldwide. Under the
    terms of the collaboration, Invitrogen is responsible for sales,
    marketing and technical support, while we are responsible for
    the manufacture of the collaboration products. As Invitrogen is
    solely responsible for the sales and marketing support of the
    collaboration, our continued growth and profitability related to
    these products depends on the extent to which Invitrogen is
    successful in penetrating the oligo market and selling the
    collaboration products. If Invitrogen is not successful in
    selling the collaboration products, our business, financial
    condition and results of operations may suffer.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">We have a
    limited history of commercial sales of systems and consumable
    products, and our success depends on our ability to develop
    commercially successful products and on market acceptance of our
    new and relatively unproven technologies.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We may not possess all of the resources, capability and
    intellectual property necessary to develop and commercialize all
    the products or services that may result from our technologies.
    Sales of our genotyping and gene
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    3
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    expression systems only began in 2003, and some of our other
    technologies are in the early stages of commercialization or are
    still in development. You should evaluate us in light of the
    uncertainties and complexities affecting similarly situated
    companies developing tools for the life sciences and
    pharmaceutical industries. We must conduct a substantial amount
    of additional research and development before some of our
    products will be ready for sale, and we currently have fewer
    resources available for research and development activities than
    many of our competitors. We may not be able to develop or launch
    new products in a timely manner, or at all, or they may not meet
    customer requirements or be of sufficient quality or at a price
    that enables us to compete effectively in the marketplace.
    Problems frequently encountered in connection with the
    development or early commercialization of products and services
    using new and relatively unproven technologies might limit our
    ability to develop and successfully commercialize these products
    and services. In addition, we may need to enter into agreements
    to obtain intellectual property necessary to commercialize some
    of our products or services, which may not be available on
    favorable terms, or at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Historically, life sciences and pharmaceutical companies have
    analyzed genetic variation and biological function using a
    variety of technologies. In order to be successful, our products
    must meet the commercial requirements of the life sciences and
    pharmaceutical industries as tools for the large-scale analysis
    of genetic variation and biological function.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Market acceptance will depend on many factors, including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    our ability to demonstrate to potential customers the benefits
    and cost effectiveness of our products and services relative to
    others available in the market;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    the extent and effectiveness of our efforts to market, sell and
    distribute our products;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    our ability to manufacture products in sufficient quantities
    with acceptable quality and reliability and at an acceptable
    cost;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    the willingness and ability of customers to adopt new
    technologies requiring capital investments;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    the extended time lag and sales expenses involved between the
    time a potential customer is contacted on a possible sale of our
    products and services and the time the sale is consummated or
    rejected by the customer.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Any
    inability to adequately protect our proprietary technologies
    could harm our competitive position.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our success will depend in part on our ability to obtain patents
    and maintain adequate protection of our intellectual property in
    the United States and other countries. If we do not protect our
    intellectual property adequately, competitors may be able to use
    our technologies and thereby erode our competitive advantage.
    The laws of some foreign countries do not protect proprietary
    rights to the same extent as the laws of the United States, and
    many companies have encountered significant problems in
    protecting their proprietary rights abroad. These problems can
    be caused by the absence of rules and methods for defending
    intellectual property rights.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The patent positions of companies developing tools for the life
    sciences and pharmaceutical industries, including our patent
    position, generally are uncertain and involve complex legal and
    factual questions. We will be able to protect our proprietary
    rights from unauthorized use by third parties only to the extent
    that our proprietary technologies are covered by valid and
    enforceable patents or are effectively maintained as trade
    secrets. We intend to apply for patents covering our
    technologies and products, as we deem appropriate. However, our
    patent applications may be challenged and may not result in
    issued patents or may be invalidated or narrowed in scope after
    they are issued. Questions as to inventorship may also arise.
    For example, a former employee recently filed a complaint
    against us, claiming he is entitled to be named as joint
    inventor of certain of our U.S.&#160;patents and pending U.S.
    and foreign patents and seeking a judgment that the related
    patents and applications are unenforceable. Any finding that our
    patents and applications are unenforceable could harm our
    ability to prevent others from practicing the related
    technology, and a finding that others have inventorship rights
    to our patents and applications could require us to obtain
    licenses to practice the technology, which may not be available
    on favorable terms, if at all.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, our existing patents and any future patents we
    obtain may not be sufficiently broad to prevent others from
    practicing our technologies or from developing competing
    products. There also is risk that others may independently
    develop similar or alternative technologies or design around our
    patented technologies. Also, our
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    4
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    patents may fail to provide us with any competitive advantage.
    We may need to initiate additional lawsuits to protect or
    enforce our patents, or litigate against third party claims,
    which would be expensive and, if we lose, may cause us to lose
    some of our intellectual property rights and reduce our ability
    to compete in the marketplace. Furthermore, these lawsuits may
    divert the attention of our management and technical personnel.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We also rely upon trade secret protection for our confidential
    and proprietary information. We have taken security measures to
    protect our proprietary information. These measures, however,
    may not provide adequate protection for our trade secrets or
    other proprietary information. We seek to protect our
    proprietary information by entering into confidentiality
    agreements with employees, collaborators and consultants.
    Nevertheless, employees, collaborators or consultants may still
    disclose our proprietary information, and we may not be able to
    meaningfully protect our trade secrets. In addition, others may
    independently develop substantially equivalent proprietary
    information or techniques or otherwise gain access to our trade
    secrets.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    sales, marketing and technical support organization may limit
    our ability to sell our products.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently have fewer resources available for sales and
    marketing and technical support services as compared to some of
    our primary competitors. In order to effectively commercialize
    our genotyping and gene expression systems and other products to
    follow, we will need to expand our sales, marketing and
    technical support staff both domestically and internationally.
    We may not be successful in establishing or maintaining either a
    direct sales force or distribution arrangements to market our
    products and services. In addition, we compete primarily with
    much larger companies that have larger sales and distribution
    staffs and a significant installed base of products in place,
    and the efforts from a limited sales and marketing force may not
    be sufficient to build the market acceptance of our products
    required to support continued growth of our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">If we are
    unable to develop and maintain operation of our manufacturing
    capability, we may not be able to launch or support our products
    in a timely manner, or at all.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We currently possess only one facility capable of manufacturing
    our products and services for both sale to our customers and
    internal use. If a natural disaster were to significantly damage
    our facility or if other events were to cause our operations to
    fail, these events could prevent us from developing and
    manufacturing our products and services. Also, many of our
    manufacturing processes are automated and are controlled by our
    custom-designed Laboratory Information Management System (LIMS).
    Additionally, as part of the decoding step in our array
    manufacturing process, we record several images of each array to
    identify what bead is in each location on the array and to
    validate each bead in the array. This requires significant
    network and storage infrastructure. If either our LIMS system or
    our networks or storage infrastructure were to fail for an
    extended period of time, it would adversely impact our ability
    to manufacture our products on a timely basis and may prevent us
    from achieving our expected shipments in any given period.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">If we are
    unable to find third-party manufacturers to manufacture
    components of our products, we may not be able to launch or
    support our products in a timely manner, or at all.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The nature of our products requires customized components that
    currently are available from a limited number of sources. For
    example, we currently obtain the fiber optic bundles and
    BeadChip slides included in our products from single vendors. If
    we are unable to secure a sufficient supply of those or other
    product components, we will be unable to meet demand for our
    products. We may need to enter into contractual relationships
    with manufacturers for commercial-scale production of some of
    our products, or develop these capabilities internally, and we
    cannot assure you that we will be able to do this on a timely
    basis, for sufficient quantities or on commercially reasonable
    terms. Accordingly, we may not be able to establish or maintain
    reliable, high-volume manufacturing at commercially reasonable
    costs.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">We may
    encounter difficulties in integrating recently completed or
    future acquisitions that could adversely affect our
    business.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In April 2005, we acquired CyVera Corporation and may in the
    future acquire technology, products or businesses related to our
    current or future business. We have limited experience in
    acquisition activities and may have to devote
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    5
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    substantial time and resources in order to complete
    acquisitions. Further, these potential acquisitions entail
    risks, uncertainties and potential disruptions to our business.
    For example, we may not be able to successfully integrate a
    company&#146;s operations, technologies, products and services,
    information systems and personnel into our business. An
    acquisition may further strain our existing financial and
    managerial resources, and divert management&#146;s attention
    away from our other business concerns. In connection with the
    CyVera acquisition, we assumed certain liabilities and hired
    certain employees of CyVera, which is expected to continue to
    result in an increase in our research and development expenses
    and capital expenditures. There may also be unanticipated costs
    and liabilities associated with an acquisition that could
    adversely affect our operating results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">We may
    encounter difficulties in managing our growth. These
    difficulties could increase our losses.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We expect to experience rapid and substantial growth in order to
    achieve our operating plans, which will place a strain on our
    human and capital resources. If we are unable to manage this
    growth effectively, our losses could increase. Our ability to
    manage our operations and growth effectively requires us to
    continue to expend funds to enhance our operational, financial
    and management controls, reporting systems and procedures and to
    attract and retain sufficient numbers of talented employees. If
    we are unable to scale up and implement improvements to our
    manufacturing process and control systems in an efficient or
    timely manner, or if we encounter deficiencies in existing
    systems and controls, then we will not be able to make available
    the products required to successfully commercialize our
    technology. Failure to attract and retain sufficient numbers of
    talented employees will further strain our human resources and
    could impede our growth.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">We may
    need additional capital in the future. If additional capital is
    not available on acceptable terms, we may have to curtail or
    cease operations.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our future capital requirements will be substantial and will
    depend on many factors including our ability to successfully
    market our genetic analysis systems and services, the need for
    capital expenditures to support and expand our business, the
    progress and scope of our research and development projects, the
    filing, prosecution and enforcement of patent claims, the
    outcome of our legal proceedings with Affymetrix, the defense of
    any future litigation involving us and the need to enter into
    collaborations with other companies or acquire other companies
    or technologies to enhance or complement our product and service
    offerings. We anticipate that our current cash and cash
    equivalents, revenue from sales and funding from grants will be
    sufficient to fund our anticipated operating needs, barring
    unforeseen developments. However, this expectation is based upon
    on our current operating plan, which may change as a result of
    many factors. Consequently, we may need additional funding in
    the future. Our inability to raise capital would seriously harm
    our business and product development efforts. In addition, we
    may choose to raise additional capital due to market conditions
    or strategic considerations, such as an acquisition, even if we
    believe we have sufficient funds for our current or future
    operating plans. To the extent that additional capital is raised
    through the sale of equity, the issuance of these securities
    could result in dilution to our stockholders.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have no credit facility or committed sources of capital
    available as of April&#160;2, 2006. To the extent operating and
    capital resources are insufficient to meet future requirements,
    we will have to raise additional funds to continue the
    development and commercialization of our technologies. These
    funds may not be available on favorable terms, or at all. If
    adequate funds are not available on attractive terms, we may be
    required to curtail operations significantly or to obtain funds
    by entering into financing, supply or collaboration agreements
    on unattractive terms.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">If we
    lose our key personnel or are unable to attract and retain
    additional personnel, we may be unable to achieve our
    goals.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We are highly dependent on our management and scientific
    personnel, including Jay Flatley, our president and chief
    executive officer, and John Stuelpnagel, our senior vice
    president and chief operating officer. The loss of their
    services could adversely impact our ability to achieve our
    business objectives. We will need to hire additional qualified
    personnel with expertise in molecular biology, chemistry,
    biological information processing, sales, marketing and
    technical support. We compete for qualified management and
    scientific personnel with other life science companies,
    universities and research institutions, particularly those
    focusing on genomics. Competition for these individuals,
    particularly in the San&#160;Diego area, is intense, and the
    turnover rate can be high. Failure to attract
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    6
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    and retain management and scientific personnel would prevent us
    from pursuing collaborations or developing our products or
    technologies.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our planned activities will require additional expertise in
    specific industries and areas applicable to the products
    developed through our technologies, including the life sciences
    and healthcare industries. Thus, we will need to add new
    personnel, including management, and develop the expertise of
    existing management. The failure to do so could impair the
    growth of our business.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">A
    significant portion of our sales are to international
    customers.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Approximately 47% and 42% of our revenue for the three months
    ended April&#160;2, 2006 and April&#160;3, 2005, respectively,
    was derived from customers outside the United States. During
    fiscal 2005, 38% of our revenue came from customers outside the
    United States, as compared to 52% in fiscal 2004. We intend to
    continue to expand our international presence and export sales
    to international customers and we expect the total amount of
    <FONT style="white-space: nowrap">non-U.S.&#160;sales</FONT>
    to continue to grow. Export sales entail a variety of risks,
    including:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    currency exchange fluctuations;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    unexpected changes in legislative or regulatory requirements of
    foreign countries into which we import our products;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    difficulties in obtaining export licenses or other trade
    barriers and restrictions resulting in delivery delays;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    significant taxes or other burdens of complying with a variety
    of foreign laws.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, sales to international customers typically result
    in longer payment cycles and greater difficulty in accounts
    receivable collection. We are also subject to general
    geopolitical risks, such as political, social and economic
    instability and changes in diplomatic and trade relations. One
    or more of these factors could have a material adverse effect on
    our business, financial condition and operating results.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    success depends upon the continued emergence and growth of
    markets for analysis of genetic variation and biological
    function.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We design our products primarily for applications in the life
    sciences and pharmaceutical industries. The usefulness of our
    technology depends in part upon the availability of genetic data
    and its usefulness in identifying or treating disease. We are
    initially focusing on markets for analysis of genetic variation
    and biological function, namely SNP genotyping and gene
    expression profiling. Both of these markets are new and
    emerging, and they may not develop as quickly as we anticipate,
    or reach their full potential. Other methods of analysis of
    genetic variation and biological function may emerge and
    displace the methods we are developing. Also, researchers may
    not seek or be able to convert raw genetic data into medically
    valuable information through the analysis of genetic variation
    and biological function. In addition, factors affecting research
    and development spending generally, such as changes in the
    regulatory environment affecting life sciences and
    pharmaceutical companies, and changes in government programs
    that provide funding to companies and research institutions,
    could harm our business. If useful genetic data is not available
    or if our target markets do not develop in a timely manner,
    demand for our products may grow at a slower rate than we
    expect, and we may not be able to achieve or sustain
    profitability.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">We expect
    that our results of operations will fluctuate. This fluctuation
    could cause our stock price to decline.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Our revenue is subject to fluctuations due to the timing of
    sales of high-value products and services projects, the impact
    of seasonal spending patterns, the timing and size of research
    projects our customers perform, changes in overall spending
    levels in the life sciences industry, the timing and amount of
    government grant funding programs and other unpredictable
    factors that may affect customer ordering patterns. Given the
    difficulty in predicting the timing and magnitude of sales for
    our products and services, we may experience
    <FONT style="white-space: nowrap">quarter-to-quarter</FONT>
    fluctuations in revenue resulting in the potential for a
    sequential decline in quarterly revenue. A large portion of our
    expenses are relatively fixed, including expenses for
    facilities, equipment and personnel. In addition, we expect
    operating expenses to continue to increase significantly.
    Accordingly, if revenue does not grow as anticipated, we may not
    be
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    7
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    able to achieve and maintain profitability. Any significant
    delays in the commercial launch of our products, unfavorable
    sales trends in our existing product lines, or impacts from the
    other factors mentioned above, could adversely affect our
    revenue growth in 2006 or cause a sequential decline in
    quarterly revenues. Due to the possibility of fluctuations in
    our revenue and expenses, we believe that quarterly comparisons
    of our operating results are not a good indication of our future
    performance. If our operating results fluctuate or do not meet
    the expectations of stock market analysts and investors, our
    stock price probably would decline.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">RISKS
    RELATED TO OWNING OUR COMMON STOCK</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Our
    poison pill, provisions of our charter documents and Delaware
    General Corporation Law may deter or prevent a business
    combination that may be favorable to you.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Provisions of our charter documents could deter or prevent a
    third party from acquiring us, even if doing so would be
    beneficial to our stockholders. These provisions include:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    establishing a classified board of directors, so that only a
    portion of our total board can be elected at each annual meeting;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    setting limitations on the removal of our directors;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    granting our board of directors the authority to issue
    &#147;blank check&#148; preferred stock without stockholder
    approval;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    prohibiting cumulative voting in the election of our directors,
    which would permit less than a majority of stockholders to elect
    directors;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    limiting our stockholders&#146; ability to call special
    meetings;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    prohibiting stockholder action by written consent.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have also established a rights agreement, also called a
    &#147;poison pill.&#148; Generally, our rights agreement permits
    our existing stockholders to purchase a large number of our
    shares at a substantial discount to the market price if a third
    party attempts to gain control of a sufficient equity position
    in us. Our rights agreement could have the effect of deterring
    or preventing a third party from acquiring us in a transaction
    that might be favorable to you.
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    In addition, Section&#160;203 of the Delaware General
    Corporation Law generally prohibits us from engaging in any
    business combination with certain persons who own 15% or more of
    our outstanding voting stock or any of our associates or
    affiliates who at any time in the past three years have owned
    15% or more of our outstanding voting stock. These provisions
    could adversely affect the price that investors are willing to
    pay for shares of our common stock and could prevent you from
    realizing any premium that stockholders may otherwise receive in
    connection with a corporate takeover.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">We may
    invest or spend the proceeds of this offering in ways with which
    you may not agree and that may not earn a return for our
    stockholders.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will retain broad discretion over the use of the proceeds
    from any offering we make pursuant to this prospectus. You may
    not agree with the way we decide to use those proceeds, and our
    use of the proceeds may not yield a significant return or any
    return at all for our stockholders.
</DIV>

<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">We do not
    intend to pay cash dividends on our common stock in the
    foreseeable future.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We have not declared or paid any cash dividends on our common
    stock or other securities, and we currently do not anticipate
    paying any cash dividends in the foreseeable future.
    Accordingly, our stockholders will not realize a return on their
    investment unless the trading price of our common stock
    appreciates. We cannot assure you that our common stock will
    appreciate in value after the offering or even maintain the
    price at which you purchased your shares.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    8
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Market
    volatility may affect our stock price, and the value of your
    investment in our common stock may experience sudden
    decreases.</FONT></B>
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    There has been, and will likely continue to be, significant
    volatility in the market price of securities of life sciences
    and biotechnology companies, including us. These fluctuations
    can be unrelated to the operating performance of these
    companies. During the period from January&#160;1, 2004 to
    May&#160;10, 2006, the lowest and highest reported trading
    prices of our common stock on the Nasdaq National Market were
    $4.23 and $32.00, respectively. Factors such as the following
    could cause the market price of our common stock to fluctuate
    substantially:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    announcements of new products or services by us or our
    competitors;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    litigation involving or affecting us;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    quarterly fluctuations in our or other companies&#146; financial
    results;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    shortfalls in our actual financial results compared to our
    guidance or the forecasts of stock market analysts;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    acquisitions or strategic alliances by us or our competitors;
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    the gain or loss of a significant customer;&#160;and
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    general conditions in our industry and in the financial markets.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    A decline in the market price of our common stock could cause
    you to lose some or all of your investment and may adversely
    impact our ability to attract and retain employees, acquire
    other companies or businesses and raise capital. In addition,
    stockholders may initiate securities class action lawsuits if
    the market price of our stock drops significantly, which may
    cause us to incur substantial costs and could divert the time
    and attention of our management.
</DIV>
<A name='122'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 14pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Use of
    Proceeds</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We will specify, in a post-effective amendment to the
    registration statement of which this prospectus is a part, in an
    accompanying prospectus supplement or in a document incorporated
    by reference into this prospectus, how we intend to use the net
    proceeds received by us from any offerings we make pursuant to
    this prospectus.
</DIV>
<A name='123'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 14pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Where You
    Can Find More Information</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We file annual, quarterly and current reports, proxy statements
    and other information with the SEC. Our SEC filings are
    available to the public over the Internet at the SEC&#146;s
    website at <I>www.sec.gov.</I> The SEC&#146;s website contains
    reports, proxy and information statements and other information
    regarding issuers, such as us, that file electronically with the
    SEC. You may also read and copy any document we file with the
    SEC at the SEC&#146;s Public Reference Room at 100 F Street,
    N.E., Room&#160;1580, Washington,&#160;D.C. 20549. You may also
    obtain copies of these documents at prescribed rates by writing
    to the SEC. Please call the SEC at
    <FONT style="white-space: nowrap">1-800-SEC-0330</FONT>
    for further information on the operation of its Public Reference
    Room. We maintain a website at <I>www.illumina.com.</I> We have
    not incorporated by reference into this prospectus the
    information in, or that can be accessed through, our or the
    SEC&#146;s website, and you should not consider it to be a part
    of this prospectus.
</DIV>
<A name='124'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 14pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Incorporation
    of Certain Documents by Reference</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The SEC allows us to &#147;incorporate by reference&#148; into
    this prospectus the information we have filed with the SEC. The
    information we incorporate by reference into this prospectus is
    an important part of this prospectus. Any statement in a
    document the we filed with the SEC prior to the date of this
    prospectus and which is incorporated by reference into this
    prospectus will be considered to be modified or superseded to
    the extent a statement contained in this prospectus or any other
    subsequently filed document that is incorporated by reference
    into this prospectus modifies or supersedes that statement. The
    modified or superseded statement will not be considered to be a
    part of this prospectus, except as modified or superseded.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    9
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN LOGICAL PAGE -->

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    We incorporate by reference into this prospectus the information
    contained in the documents listed below, which is considered to
    be a part of this prospectus:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0">

<TR>
    <TD width="3%"></TD>
    <TD width="97%"></TD>
</TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    our annual report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the fiscal year ended January&#160;1, 2006, filed with the
    SEC on March&#160;6, 2006 (file no.
    <FONT style="white-space: nowrap">000-30361);</FONT>
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    our quarterly report on
    <FONT style="white-space: nowrap">Form&#160;10-Q</FONT>
    for the fiscal quarter ended April&#160;2, 2006, filed with the
    SEC on May&#160;8, 2006 (file no.
    <FONT style="white-space: nowrap">000-30361);</FONT>
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    our current report on
    <FONT style="white-space: nowrap">Form&#160;8-K,</FONT>
    filed with the SEC on March&#160;29, 2006 (file
    <FONT style="white-space: nowrap">no.&#160;000-30361);</FONT>
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    the description of our common stock contained in our
    registration statement on
    <FONT style="white-space: nowrap">Form&#160;8-A,</FONT>
    filed with the SEC on April&#160;14, 2000, including any
    amendments or reports filed for the purpose of updating such
    description (file
    <FONT style="white-space: nowrap">no.&#160;000-30361);</FONT>
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    The description of our preferred stock purchase rights contained
    in our registration statement on
    <FONT style="white-space: nowrap">Form&#160;8-A,</FONT>
    filed with the SEC on May&#160;14, 2001, including any
    amendments or reports filed for the purpose of updating such
    description (file no.
    <FONT style="white-space: nowrap">000-30361);&#160;and</FONT>
</TD>
</TR>

<TR style="line-height: 6pt; font-size: 1pt"><TD>&nbsp;</TD></TR>

<TR valign="top" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <TD>    &#149;&#160;&#160;
</TD>
    <TD align="left">    all filings we make with the SEC under Sections&#160;13(a),
    13(c), 14 or 15(d) of the Securities Exchange Act of 1934 after
    the date of this prospectus but prior to the termination of the
    offering of the securities covered by this prospectus.
</TD>
</TR>

</TABLE>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    You may request a copy of these filings, at no cost, by writing
    or telephoning us at the following address:
</DIV>

<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Illumina, Inc.<BR>
    9885 Towne Centre Drive<BR>
    San&#160;Diego, California 92121<BR>
    <FONT style="white-space: nowrap">(858)&#160;202-4500</FONT>
</DIV>
<A name='125'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 14pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Legal
    Matters</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    The validity of the shares of common stock offered by this
    prospectus will be passed upon for us by Dewey Ballantine LLP,
    New York, NY.
</DIV>
<A name='126'>
<DIV style="margin-top: 12pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; font-size: 14pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

    <B><FONT style="font-family: 'Times New Roman', Times">Experts</FONT></B>
</DIV>
</A>
<DIV style="margin-top: 6pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="left" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    Ernst&#160;&#38; Young LLP, independent registered public
    accounting firm, has audited our consolidated financial
    statements and schedule included in our Annual Report on
    <FONT style="white-space: nowrap">Form&#160;10-K</FONT>
    for the year ended January&#160;1, 2006, and management&#146;s
    assessment of the effectiveness of our internal control over
    financial reporting as of January&#160;1, 2006, as set forth in
    their reports, which are incorporated by reference into this
    prospectus and elsewhere in the registration statement. Our
    financial statements and schedule and management&#146;s
    assessment are incorporated by reference in reliance on
    Ernst&#160;&#38; Young LLP&#146;s reports, given on their
    authority as experts in accounting and auditing.
</DIV>

<P align="center" style="font-size: 10pt; font-family: 'Times New Roman', Times; color: #000000; background: #FFFFFF">
    <BR>
    10
</DIV><!-- END LOGICAL PAGE -->
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="width: 87%; margin-left: 6%"><!-- BEGIN PAGE WIDTH -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 3pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=0 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 18pt">3,500,000&#160;Shares
    </FONT>
</DIV>

<DIV style="margin-top: 60pt; font-size: 1pt">&nbsp;</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <IMG src="a42519fa4251900.gif" alt="(ILLUMINA LOGO)"><FONT style="font-size: 18pt">
    </FONT>
</DIV>

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <FONT style="font-size: 18pt">Common Stock
    </FONT>
</DIV>

<CENTER style="font-size: 1pt; width: 22%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=102 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt">PROSPECTUS SUPPLEMENT</FONT></B>
</DIV>

<CENTER style="font-size: 1pt; width: 22%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=102 -->

<DIV align="center" style="margin-left: 0%; margin-right: 0%; text-indent: 0%; font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">
    <B><FONT style="font-size: 18pt">Goldman, Sachs&#160;&#038;
    Co.</FONT></B>
</DIV>

<DIV style="margin-top: 3pt; font-size: 1pt">&nbsp;</DIV>

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 1pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=0 -->

<CENTER style="font-size: 1pt; width: 100%; border-bottom: 3pt solid #000000"></CENTER><!-- callerid=999 iwidth=455 length=0 -->

<P align="left" style="font-size: 10pt; font-family: Arial, Helvetica; color: #000000; background: #FFFFFF">

</DIV><!-- END PAGE WIDTH -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>a42519fa4251900.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a42519fa4251900.gif
M1TE&.#EAE0!$`/?_`/[<H?ZS.O_WZO[TW_W%8OW&9?V_5/[HO_[EN?[BK?W6
MC_W1@_W,=?[&;J.CH]'1T71T=/3T]+JZNE)24NGIZ6EI:=W=W9>7EXR,C%U=
M78"`@,;&QJZNKO_[]?_Y[_[KQO_TX/[JQ/[NT/[<GO[IP/_Z\O[<G_[LR/_S
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MLOW.>/_JR?[KR/V\3O[5C?[4C/W!6OW`6/_3C__MSO_LS__LSO_;H__:H?W4
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M@/V[3/[0@/[1@T9&1O___R'Y!`$``/\`+`````"5`$0```C_`/\)'$BPH,&#
M"!,J7,BP88D7'V2,*FCD1YIMX0J6"Q%BAJ*&($.*'$FR),,<OYS$L=&+()H!
M16+@8#&0QX<N>#X(46&RI\^?0!NN@.'!6XL_`V\$PL-)1!@7`^>\J.+D18IK
M0;-JW3J2R0<B)(9,&>BEQ8L<*TR@&.A!2XP86FR5X$JWKMU_:H;@.`:%Y\`[
M3[2-J%0PQ)(EV'3<7<SX9XDI*/P29.%BK4$4+F@VWLRYL^?/H$.+'HTP"`@4
M/`QZ`.'HX.J/I&/7]9`H!9@O:@C::92"QJL.!,=4&Y+LD.SC6GWXX/(A"3F"
ML@[`6%$#P<`@[DZ8::%G&?+O/@\-_ZIS0@D\@H+R"9.2#LE`1S3D#-@2"0OX
M^R2?*&$TST\A@MG0@8,XD*Q!T`(C,)*$(2#@YR!(/"S`QA7/`#=0%I&X4<!_
M!.F0"QL$`/#@B`V!T.!!/0AP4`<]6`C>`_[$Z(]!,,8(`8DXBE1CC#3*>&..
M0/X3`0<.2-"CC$?Z\Z-H`IPAQ"H&M8%$&?@8U`,2M-AS7P4R8E#0CC-^Z>-H
M`CB3QQNHM$+0'7XD4L,^HG2H#QUZD%(+>#+&2`%!8":Y)&@[T`!.$Z%\0M`F
MQW`QB#H-$,2-#3"(<0HF>.;Y`)]Y^CD:%/>0@(@;W1#$SRPA/$$`,P3M<0P:
M8!B02J4Q9O\@)I*S*CD:*P8PL(XDCQ!TSAYD7!$`-00U4P`9FGQC#'@;9*"D
M!;6&B:F-I+D2`#&/`%$0(7#@HDQ!)30`!S+L!/E/G[7^:>YW$4C@`+0*H3NM
MK>N"%T$%$%Q0`0?Q9IINO>!=P($_&&@@:T+R#K2CNG=9\,">"5'P`+Q<24QQ
M2`Y?>A`$$?B3@0,.7`#!R$;.*ZW"8Q(D,LD)63#RR`2Y//(%`CV@09X38'`Q
M!1A,D&<%)1LD,\P$2?`RS>?>G*<&&RQD@;YY^I.SQ@)=(($_%S@PLHP.1*LI
M01!PC;"_-8]Y0=1YEBR!SVC[4T$$29[\CP,^1J!TVQK`;1`%8;?_7;=`]T+0
MK,ABF_SU0'W[TS5""2^,@=\R;G`UY&[KC3*M`]%M8^)^:V#0VI3+^#;@1%Z:
M^.*7\_@OV(4?U+C?^#J;9P9L2[UUU*B7C;E`FJ,=.]I-%SW[!1L\\,`%M1.\
M<>NZJSZONJ>/O3N8,6H`\;G)QSA!\+S/[C5!O7-]_0-<IDS0P!/P6]"]>5J.
M.//GDITZ]/`;GGJ,7D8K]?69YWEQPG.+6M`&$@'9.>]\%R,(!?+$O??%*'?Q
MVUWSZ/=`Z1T03!EPWT`,J+B#=$Q&`P1@^#QWD,G%B&H@N1L$_Q$]^SVO("UT
MG?S`A#2#/$Y&_"-(^3IXOX*$+X$$M-1(_WJWPA@V3VX1I)<#>2C#Z0GQ(+V;
M0$*,*$+Y&>2)KB/2RT9FP"+"#X!)I"`3X^9"@_2.84O,716IE1`L#H1GV6N;
M%RM8Q@G"L'X]S",4S6<0*EKQC`IQ8P!#5S\C)A&)"[LC'9MX02N"CX^*'.,:
ME7@0-YXM:A#``,A`9D@6?M&1B63=(LFH1S-"4I22_.,I"8)%,$U``AH<Y!@%
M8D@PAC*-"0E?'1_)QN6-<I)H'`@6;RBU6'9OE+3\I`3#&,G\'62')P-C_WK9
M1^8!,Y`RHEKBU/?,0BKS@'8DR-TF8$SJ[7*:E(RD&E5)S2MF4YB10\@"O8G,
M#X*3F;S$G]"R=__.8Z83E>N4("#;^,YDQJB&D9RE)Y'Y#U!"T@)1TP"\*."`
M./93EL%<:"H%NDIXGG`@Q/0'"H5T-X9VTJ'MU"CDDG?1@?IRH^!T:24+>DBW
M;7*<]%0H2O])@3CB;&!.7"8Z,^I'CJ:4E33]1TC;5H$-Y'2%.T6C!:#Y,X?-
MT)%#G:(UV?E/I'Y499#CV(Y6Z"Z0C71NF]S;)@=8$`D8+%8:*!E%T_K&3:Y0
M86M-2%D=@,*Y@NQ+><WE)G/X#PH0+D85P(#&_-I`@#GVL9"-K&0G2]G*3D,5
MBS""08"@BS5HMB!=D,</@E!9Y``A!3,(0PU$0)`N[(`)*:A!%@@""!S_S&`$
MEW!1:4>SAB.80P36J`%!M)`&)WQ``8T@B`ER4`4I5&>WL=D!(G81`AH0@"!"
MJ(<5CB"(>!!$"8&PPA:^<`;HDH8*L#!!'A@`#8*4(0GO2`(D[#.06\3"!&\P
M1`_,2QHH]*$`_=`M#TS1!P)$HR!9*,45QD%?_CKXP1".L(0EVP$BA&`,DA$(
M"^2PB&$8A!Y4`$85)MP9+TA!!")@P@H(<H,#Q"$&+9@$08K0!%Z<8`=M(/%F
M?/&#&]S@!,<@2`Z(X(%VD&`)!#F!%8```QG(0,>-D08)S,`%$HQ@+@*AP@_J
M8`<9F(`@3;!$)WBQ!1M`F3'!2``?^""&3,PX+`%'F$$Q%#,0=-B`$IX8`2#.
=S)@Y1"$**\CP/T#@@RA`I2!_\`$HQL)GA@0$`#L_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a42519fz4251903.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a42519fz4251903.gif
M1TE&.#EA;`&F`.9_`/CX^%!04)R<G+2TM+*RLH2$A)"0D&EI:71T=#`P,'!P
M<"`@((R,C+R\O*ZNKF5E97Q\?'=W=WY^?IF9F;FYN5U=78J*BA`0$$U-36!@
M8*JJJI65E9J:FK:VMJ:FIGAX>)^?G[BXN(B(B*RLK(*"@D5%13<W-Z2DI(Z.
MCJ*BHEI:6BLK*P("`AL;&WIZ>I*2DH:&A@L+"U145!<7%\#`P$!`0("`@+^_
MOW-S<_#P\-#0T*"@H,_/S^#@X+"PL,+"PLO+R]+2TMS<W.GIZ>[N[M75U?O[
M^ZBHJ-O;V]/3T\/#P\'!P>OKZ\7%Q=W=W=K:VI:6ENCHZ,?'Q^;FYO?W]^/C
MX^7EY>+BXMC8V,K*RM34U/;V]L[.SLG)R>'AX=;6UNSL[-?7U][>WN3DY.?G
MY^WM[<S,S-_?W_/S\\3$Q._O[_3T]$%!0<C(R,W-S:FIJ?'Q\;&QL?7U]9>7
ME^KJZO+R\L;&QM'1T?KZ^OS\_+Z^OMG9V8&!@20D)````/___R'Y!`$``'\`
M+`````!L`:8```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4D'A@7DY8045EEIB:
MG)Z/EYF;G96IJJNLK:ZOL+&RE5M#3$-C8E\\4EB.M;>YN[V_MKBZO+ZSR\S-
MSL_0T90`='!H.7173T%=2TB,U-;8VMS>X-77V=O=W]+N[_#Q\O."0V5;1G)@
M8TA)63\WJ"RRAT\?/W\`!2J*<B]?F3%"$`:D1[&BQ8L8"P$84V8-@#5@JB`)
MDF7)C3.*-G;\&')DR9,I.7H$>?#?C789<^K<R9,5$2]1B.0H$Z7'GCMM:-S@
MH>AGT*%%CR9=JJ@,4*%$C2)5RK2GUZ]@P_YA(N3*%#)3O"`IXJ;)#:J)_\B:
M1:N6K5NXB.2>3;NV[=NN8@,+'OR.R9<G8LXX>5*$1[>_B@PC5LS8L4F\AR0G
M7MSX,6;"H$.+7K6%1Y(B7XH$X=)%R=L;5125/IUZ=>O7L1/-1JV:M>NWN4<+
M'TY\T1<@;KBXR2(%X%LE"A,=3[Z\^6OHQI$K9^[\;?3BX,,+7R,E39,T/Y3B
M9D3>/'KUP-F7/Y_^-6SQ^/.#1O/;/LQ&_/GW%DH`]F<?@?HEJ*!71B`AQ7-A
MJ`%)@P_>H$2$$SKX7!(2+NCAAR"&*.*())9HXHDHIJCBBBRVZ.*+,,8HXXPT
MUFCCC3CFJ.../#("!Q9Z=-!`$)+\&.0/3Q0)9/\'2/;H9'%&)&%2"".`@`(*
M5CABA!8F=:"!``Q`D64C6W;Y99AC/JGF8$9PP85J;5#PQAP%2)!F(D;PP(-J
M4E!P!!0%0'`G(GGN&42??P8ZZ)J,]M2#&TY$44412L0A@`41%/#=(4)P(8:D
M6OS@PZ69,M+IIU5HH<2HF!;0Z*L]X:%$$%-L082#`^S`P`<X`"';#4F00449
M3]@Q``B[]JJ($<#62JRQR/+J*ZS48C1%`SSTP,0483011[0X@*"(%PWHX`48
M4WR1AJ68XG#$N.6>F^ZZI+I;[;T5)3%`&G=@<5P#&DP``P(X0*&(%@,T$006
M160!\`0%$&QP(@@KS+#_PP%'7#"^',O#Q1L=T-"$$@TXL(,!$N"P<2(\@"PR
MR0Z`@++*$R/2<L@CERQSRBMW[',T8W#@@0-Q^/#&#B\4$('*XB8BA@!#Q^'`
M&R`D3;"]3D--M-%5*ZWRNS^'_<P+&W`@@`!S&%``KRI/BP@`9)^--@I>JRQ$
M2G&?G7;=.&@A]M_,2$&""!:($.C5.##`B!Z#%WZXRCTGPCCAAD.`>,V`9P[+
M$1%TCC@.@C;"N>>0XZ"IZ)U'\#D$FVKN^BH40%!ZP40\0L'LX;:>2.RS@Z#[
MZ\!30@40%%#PPZ*,#%_\#[5'HKSQS0<O_?2$]4##]=ACW\,C.63OO0[4A^^,
M_PU^E&^^^38\0L/Y[-<@_ONSD,\^^NK/;[[[\.?OBOSVI^_(^O;S`_[T1\!4
M\&]^_FL$`.TWP`(Z,!('9%\"&;'`^37P@>'3`0W`)XD(GF^"BZA@^YS$F"%4
MHH0G+$(4Q)8#&US`?!?(0`X@X4'Z_2^``MP1$P;```D<(``8T``D=MC#'P9Q
MB`.P``0.@`$,O,%G.4B`_2[`P4;4L'P@5(0(SW?!&@GA"'$8@0`*<(`2].$!
MCOAB&,=8QC.F\0UK+,`#2K``-'),B@&\P`RMB,,L)F*+]\L1&1Q@AR``80`3
M^(`,$A`#!3!BD(4\9"(7V<A'.D`*)!G`'")`24?>R_\`."Q?!AQQ13_X$1&`
M+%\79W2$!CR!"%=HP@GX4`$37(`%VU.$`UP)2UG2TI8LJ"(BWM``)*C!"VE(
M@0U4`,Q<4@N/.+P`*?M8OP"N,D91X$`QU5`%7];REIY$1#:WV<U9?I,%X3R$
M%P30`"'DX`II.,$R@7E*-872?,),1"GK:8A4YO!&:3#`)9-@A@Y,DI$L8(,B
M`CK0@AXT!@E51`,$VH8D2)*3"%5HM>Y9/AKP,8#\+(0_KPFC`4!@#AH@@`/8
M:$861#01)D6I2EG:!Y=J%!$#D,`$-#"`E<JQI2^E%D?]X$Q%[+.:#,31#1[@
M`@L8H(@!2,`M@WJ(I3;UJ3[_C.I4;WJ(`3P``DZ%JE1M>J\:W',!TP0I4BV(
MHRB40`4/.,`!*H`!$[3`I2S@IUOA*E>ZVA6OZ30$$MX:U[G6]:XN-<"]=G#/
MD`[BJ#>T9HXR8`(VE*`$)EC!#/"*RT50UK*8U2QGBWJ(SUXVLYMUJ1[Q%0`<
M)F"/C("L`G%(4AAIH0\M6,`"9@!1O"IV$5?`K6YYR]G?'DRXN^VM2W?`L1RT
M=GZO?81L*4A;'>E@JIS-JR.NFUV7.E80W.VN<3FV@^?Z(0',I2$U(YM4';5P
M`:K-@$>Y9P/XLB"&\W7$>^.;3P).-X35Q:"`/]J_M8YPP#[K@0]LL(/^MN*_
M6@PP_X+OI0.SGF\!^=W?>F<KV0E7:P<7N(`"/*H#`RS`#^-E!83_*&$/-^JZ
M":"!#69L`Q\XUP\^>,6*4=EB%Z^I!A>P'OL4$,75/GC#U.VPC]?4`U/^87WI
MZX%N_^`#/Z17Q4@&L)*7_"3&@@_*3PZQ()Q\9+6REZU<5A/Y!"%"_]6@MA#,
M<H2W/*+N8<\5=KX>;(F39QKL^1W>^W,C&+N]];T9Q8,0L8;-S.'VAL@'"K`P
M^RY0`P,X>!$],`"0[9>`#.R`M&')`:0ES;X$*"#'S9!Q5'&X@!K46-"&T(&5
MGVS*'%Q@`3.4M6+]^5U![/@0(VT$J=F784H$>Q$X+/8?WO\[5`&BFA$[&'8H
M:Z!L2$C;?-4VQ+4[:H@>9."%0XTAJ%?A@V\W^WP!N#(B=-L])X,R?:TMM)SU
M.6\>TQD1V_9#MB%Q;$4DNQ`N//?]QCT(&D!3X#6X-"/RO6]",)P0WA;X!V$M
MB1:"6^(75G<AJIR!"J<W`ZXF,Z^E6V]@]QC?_U9%OQ.1\C_HX.`2O\"S`8YQ
M]FG<$0]?>,M!7'/S)4#AC;!XSSE]:06<-[\Z:&T`"EYR0_RZGR<_1,Y3L7)$
MI-P'%Q^ZQF\\=/.-,A)35T3.C=[U\E&1$E@O^Q1O+@B>"Q#<Z1QY6@M\Y@,O
M(NS&CGHA_LU8M7-;$%'T>_E2K//_`#9\$`_/@.#]<'9(<'WQ-D=$#G80Z0P8
M@+1R)S`"#<Q%8;>\$E4_1++]6?,@"T+QD#]\(?".<L/W??&X?D0/8`YY\[$]
MR737O`0Y'\C"VT_UN$>SOP.8=LB[#Y2UCSW./Y^(?+L=\DM?OL!;_>:LW]/T
MD<A\;)LN4KVOGOF3"+TA6%W[P5M?\+W^`^NE3O[RZUN_M)]TNOLK:G/?$\XF
M9_3V]:]E1XL=_)(@?GLG<0MP:O.E0?55=@7H`WZV;#107N'V".NG;1B7`#5V
M@#(6?_ZW"-<50`M@`!1'""W$4<!'"-JW"$_7???&?H:W"@)("--W>VQV8AA'
M;8J0`V07_THR^'TMZ'M#E0$$)P@]D&_G$X2Q=GXV$(*'T($X%'V\AT4DQW]S
MMH&M]WLNZ'V#<&XRQ`B!)W"$APBO%T!.>'<`2(%#A6&.@'RA%%@<>'$_-PE,
M&$!*"'522&]U:&]4R()6J')8.&8_R#WGAT,[:`AA:#]S*`@3R(/W%%V/4(C0
M%0D=R(;\IH.3>(>'D((FV(>(6(:5F(<#>$]?UXC-EGZ(%THSUWR<Z'`<Q8B0
MD(-R"(FG.`FH9S^2R&*6Z'3<EXDK:(9[2'6:N(J30(.AE`!P&$K?E8BJ>$]`
MEP@Y((R]*`VRMHMXN'ES1XV-)GS_UX.^*(U9>$\E6`AJF(J*H/^!_T2&VIB-
MN6B'M\@,&HA_NIA[^P>/_8>-J'B.><>-?JB)B!"-K%8)I816/DALGA=-AY@(
M39:.LN"*[-.)UAB/#3F/=H>.\_.-MNB),&B*E7!/M7B-\S.0SUB/`12*E$".
M(BD-I<20NU>-*<F1G1>0YT.1TQB15A=-J4"$,/F)ANB2V.:1]K.,C*"0+?D.
M)_F$9*9['T24[HB,=1>4+(=#)1D)YF4_JA"(?R>1`JF39K<*I>2.LC"42VE#
M1@F6P2>353B15XB/?Q!*7QB%G*8*2JE^XKB):#F63,D*=F8`-):7>9EO*'F4
M*NF7+-E[YOB1X?>+<6E4^FB5+XF5[\?_F*08DW4)AP8`<H+7EV*)@@A):W/Y
MEG0IF$WYBO[8A&X9EYSI?&=ID8Q0;E39=98)A7]YF5-(CV5YE=N(FODHE:G@
MB+`)=J1YF)P)D9')"#V@`*NI=JU9E`ZYDIVI2CQ)FZ!GF`'$A^O(F*I7FH<)
MG)[)A4!9?L>9?IC(=)MYG;%)EN.'0](ICY+PEM9ICX4YEX)0?.YW/MW)E@\Y
MGL')BV9YGK)9GM%9F_7)F^R)G\X)DOGIG^1YB?&)FU_IFF')H,M9CHJYD_IY
MH!?9G\\YG8-9H`0ZH+.YF!-ZGX4PBS67`&]6HF_FC`M)E-Z9F2^8C(09@-"I
MH/>(G@#ZHHJH_Z$;ZJ$&"J*#H)MY%``7B)D6&I@.*J0T"IG9V:$2NJ-)RI\R
MVIY'*H&]&:`"JJ,7:IO\&$H?Z).$X)5$BIQ&^I](RIS426XQVI%,6J3I.:4V
M>J,<"J/X2(1'-PE>^J`KBJ%LIH^_B9AH&4H?NIO6QJ8XJJ15>:7["9Z9B8M#
M:J?TJ9S82:89^J:1(*(4VHV+"J=1*GUM6HI4ZJ96.J.'>GJ4&)J7:I^`BJ!X
MJIFV*9?V,XB-@*(\>IMH:JB.NJ:=RJF;BJN#BJFA^@>KN9&.L)WE,Y^OJ:85
MV:NZ6JN1<)!]:IYI"J:VFJMP>:O)^JE0&JK^9&25P)<JVJB`^:!)*?^:J1".
MR)J6SDJKWSH)ZNF;XGFL%.JC?O"4DN"GW5JLT.JNL>IK-)D*L)JO](JNIZJI
MN^JI2QJAA0JJ%/J=BE!EY_JE=YJI*KBJ?U!*.%8)\`JIG_FDO*JL@4JMTRJM
M'SNPQTE2"IL(E)JB"WJOB%"R+=JCTT8)S7A_C/"O")NNT2JRU5JP.:JSUYJP
MB=IM]T2L#:JR^2>Q60JRAG"RY4JS/6NS-8JSK`JU42NI(ZN.\R.OCQ"5&FNJ
MQKJR+)J8Q:FMCG"Q38J3LUJS`=N<UEJE/*N'4@NNB4"N%V:Q'"6TR>FT8PJA
MBJ"UT%60@B"L2]NP39NV91JI:\NV!SNX&!O_L:U:C'5;KT.;?BWKLM<7B_U$
MCH%;JG:KKH)*M2[ZMH^JMV8[:5Q*",_'M*'[L&):M.6::$-5`SL@:#T0;1*'
M?ZB;?3^+N(UIL+O+NS=)AZC)M^=S`26(@^>VN7P*L>_8NOIZ;M17?3UGNX*[
ML7@KI1Z[GDC+M:)+"`P;2AE@N8.@`\0Y19J;MZK+L:Q;J840L^4'N-);OBG[
MF+I;G>SJL7`[CN'F:GH9`/U:/I$&O\"[NHJJO(.0`XF9I[47`)-[N\C[M)X[
MM8=+L(E+O66+J)!'C-O6P%Z;JN8JL5UZP>W6K`#,J#79N1'\N0_\I?A'L2,Z
M0QD,N7=+N!7*O(2@_[0MK*J9N[4:;+W2BKV@J[WN:,,W'++R"<-ABKZBYYZ%
M`+CG5@-[M,#3B[L<[+8I[,,I?+\Q7(.PM6U&R+A(3',<?,`;U[\<=0'C!<4C
MG+JC>;WUF[WX6L']1,9E#$+"V[MJ;*^D*,;K&W#G%D-_AL8Z;,0W6\5M_,-O
MO+B+('02!X0#?,6`YSW9T\40!\G:PV^4O$&J,'EUC&ZQ>PA]]CT4=,F_*X*B
M+,D<*,J'J$&77)"J3,E^>X.B7+J%4%[%63[I1G'6X\HR\H!ZR6"RG&;-H`,+
MULL^\,O`?,S(G,S*O,S,W,S._,S0',W2/,W47,W6?,W8G,W:O,W<O`A18/\&
M!.`!1T`!KRP(WQS.XUS.?W#.XDS.W>PD<O`%7``$2S``'K`!!6`&CA#/\US/
M]YS/^RS/]&S/^*P$[[PC>1`$2.`%0L`#-[!2%O`!;I,(";W0#?W0E_(!/\`(
M%<W0#@W1&GW0.>($81`%:#`$W4(`NN("$!`]B$#2)HW23:#2#.`"..#2AP#3
M)]TMN5+3-RW2-F($31`&0[`&0X`%3=#3-DT!RS+417W42;W2.`"^@B#41&W4
M2*W44PW4-4(&2U$63J!!(!TYA@`&7WT%84T#8XTY97W6:;W67$TC13``/V`&
M.F`&/T#0&L/6A3#7=7W7>?W/$G,P=&W7>*W7@QW_US*"!$<P`!30`!0P`$<`
M)K)#UH5P!8W]V)$]V0Q0V7Q-"%?@`8X-V9)-V32CV#+"!!.0`D>@`4>0`A/`
M`#9P-6"3%ZO=VJ\=V[/]-9%QVZX-V[)-VZ@M(R>S`7.P`09@`1*`.'>C",5]
MW,F]W)#3W(GPW,BMW,P]W#%R!A)0`-XM`6S#-(S`W=Y=)^$=+N/=W=]]WDVC
MW3`"!`@0W[/#`+]3"/`MWZ5#WXUPWY^3./7MWBEB!5!0.A#`U(\@X`1NX(Z`
MX)!3X`!>(T0@!$*`/(T0X1-."19.X0^^X1S>X1[^X2`>XB(^XB1>XB:.(UMP
M"V4``).0XD,`!BPN"2X._^,G;B);8`4]$`I`\`1&\`AU4`4Y'@9WD`4\[N-`
MK@E#7N0U'B)J,`5#$`6Y$`:\D`9H4.%D\.11S@MM\-^#0`17#N5B(.52L.5+
M_B%;0`9$4`=PP`0B01)+,-&(<.9ION9MW@UP?@ARKN9L/A)V7N8>8@5T4`=X
M0`5-[@1:``0`00:+,`5T@`:#3@138.B(?@.*K@B`[NA4`.F2GNA^GB``T`-#
M``<`(`=$8`6;#BRRX05#4`>C7NH1\1))D!*@SNJD;@6O#A"QWNGY(0=.8`5@
MH`9$,`3D\!A2T!1BX.O`+NQ/<`==P!7&CNS!K@W,[NRZCA]K@`5G,`93,`57
M(.H$1<`%=O`<BC`$>Y#MV][M=@$9B0`&Y:[MW.[M7'`7@%'MX($&"R,$3L`9
M.M`%SC'OAF#O6(#OG,$#;7`9_EX(`"_PE5'PZD[OX<$%.I`$6J`%MM$?"'((
M>0`$$3_QJ]$&_1$<&,\#&T_QOK$>#A\>5R`%60`$0-`%=M`=2M#CBB`&;;#R
M+6\'EV$A,N\T-<_R+@_S.W_RQ&$$9K`$/_`#.?\6E;XL17_T27\#3,`(1&_T
M2.\?42_TX1$E`J($5R_U#NT?7*\E2;#U78_UX:$&2*`G25`%0=\(:B#EIL'V
-D?#V:B_W9I\*@0``.S\_
`
end
</TEXT>
</DOCUMENT>
</SUBMISSION>
